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1. Preamble
Guidelines summarize and evaluate all available evidence, at the
time of the writing process, on a particular issue with the aim of
assisting physicians in selecting the best management strategies
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for an individual patient, with a given condition, taking into account
the impact on outcome, as well as the risk–benefit ratio of particu-
lar diagnostic or therapeutic means. Guidelines are no substitutes
but are complements for textbooks and cover the ESC Core Cur-
riculum topics. Guidelines and recommendations should help the
physicians to make decisions in their daily practice. However, the
final decisions concerning an individual patient must be made by
the responsible physician(s).
A large number of Guidelines have been issued in recent years
by the European Society of Cardiology (ESC) as well as by other
societies and organizations. Because of the impact on clinical prac-
tice, quality criteria for the development of guidelines have been
established in order to make all decisions transparent to the
user. The recommendations for formulating and issuing ESC
Guidelines can be found on the ESC website (http://www.
escardio.org/guidelines-surveys/esc-guidelines/about/Pages/rules-writ
ing.aspx). ESC Guidelines represent the official position of the ESC
on a given topic and are regularly updated.
Members of this Task Force were selected by the ESC to rep-
resent professionals involved with the medical care of patients
with this pathology. Selected experts in the field undertook a com-
prehensive review of the published evidence for diagnosis, manage-
ment, and/or prevention of a given condition according to ESC
Committee for Practice Guidelines (CPG) policy. A critical evalu-
ation of diagnostic and therapeutic procedures was performed
including assessment of the risk–benefit ratio. Estimates of
expected health outcomes for larger populations were included,
where data exist. The level of evidence and the strength of rec-
ommendation of particular treatment options were weighed and
graded according to pre-defined scales, as outlined in Tables 1
and 2.
The experts of the writing and reviewing panels filled in declara-
tions of interest forms of all relationships which might be perceived
as real or potential sources of conflicts of interest. These forms
were compiled into one file and can be found on the ESC
website (http://www.escardio.org/guidelines). Any changes in
declarations of interest that arise during the writing period must
be notified to the ESC and updated. The Task Force received its
entire financial support from the ESC without any involvement
from the healthcare industry.
The ESC CPG supervises and coordinates the preparation
of new Guidelines produced by Task Forces, expert groups,
or consensus panels. The Committee is also responsible for
the endorsement process of these Guidelines. The ESC Guide-
lines undergo extensive review by the CPG and external
experts. After appropriate revisions, it is approved by all the
experts involved in the Task Force. The finalized document is
approved by the CPG for publication in the European Heart
Journal.
The task of developing Guidelines covers not only the inte-
gration of the most recent research, but also the creation of edu-
cational tools and implementation programmes for the
recommendations. To implement the guidelines, condensed
pocket guidelines versions, summary slides, booklets with essential
messages, and electronic version for digital applications (smart-
phones, etc.), are produced. These versions are abridged and,
thus, if needed, one should always refer to the full text version
which is freely available on the ESC website. The National Societies
of the ESC are encouraged to endorse, translate, and implement
the ESC Guidelines. Implementation programmes are needed
because it has been shown that the outcome of disease may be
favourably influenced by the thorough application of clinical
recommendations.
Surveys and registries are needed to verify that real-life daily
practice is in keeping with what is recommended in the guidelines,
thus completing the loop between clinical research, writing of
Guidelines, and implementing them into clinical practice.
The Guidelines do not, however, override the individual respon-
sibility of health professionals to make appropriate decisions in the
circumstances of the individual patients, in consultation with that
Table 1 Classes of recommendations
Classes of 
recommendations
Definition Suggested wording to use
Class I Evidence and/or general agreement 
that a given treatment or procedure 
is beneficial, useful, effective. 
Is recommended/is 
indicated
Class II Conflicting evidence and/or a 
divergence of opinion about the 
usefulness/efficacy of the given 
treatment or procedure. 
    Class IIa Weight of evidence/opinion is in 
favour of usefulness/efficacy. 
Should be considered
    Class IIb Usefulness/efficacy is less well 
established by evidence/opinion. 
May be considered
Class III Evidence or general agreement that 
the given treatment or procedure 
is not useful/effective, and in some 
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patient, and, where appropriate and necessary, the patient’s guar-
dian or carer. It is also the health professional’s responsibility to
verify the rules and regulations applicable to drugs and devices at
the time of prescription.
2. Introduction
Cardiovascular diseases (CVDs) are the leading cause of death and
disability in Europe, posing a great social and economic burden.
Coronary artery disease (CAD) is the cause of death in a large per-
centage of individuals, but stroke, renal failure, and complications
from severe ischaemia of the lower extremities also contribute
to an adverse prognosis.
Since atherosclerosis is a systemic disease, physicians must
appreciate the importance of detecting atherosclerosis in other vas-
cular beds in order to establish the correct treatment to prevent
organ damage. As shown recently by the Reduction of Athero-
thrombosis for Continued Health (REACH) Registry, a substantial
percentage of patients with chronic CAD have associated cerebro-
vascular disease, lower extremity artery disease (LEAD), or both.1
This is the first document produced by the ESC addressing
different aspects of peripheral artery diseases (PAD). This task
has been undertaken because an increasing proportion of patients
with heart disease need to be assessed for vascular problems in
other territories, both symptomatic and asymptomatic, that may
affect their prognosis and treatment strategy. It is also recognized
that patients with PAD will probably die from CAD.2
In this document the term PAD is used to include all vascular
sites, including carotid, vertebral, upper extremity, mesenteric,
renal, and lower extremity vessels. Diseases of the aorta are not
covered.
Although different disease processes may cause PAD, the Task
Force decided to focus on atherosclerosis. Other aetiologies,
specific for different vascular territories, are mentioned but not
discussed.
Atherosclerosis in the peripheral arteries is a chronic, slowly
developing condition causing narrowing of the arteries. Depending
on the degree of narrowing at each vascular site, a range of severity
of symptoms may occur, while many patients will remain asympto-
matic throughout their life. Occasionally acute events occur, often
associated with thrombosis and/or embolism and/or occlusion of a
major artery.
In the first section of this document the general issues are
addressed, whereas the detailed clinical presentations are
covered in specific sections for each vascular site. Special emphasis
is put on multisite artery disease (e.g. patients with CAD plus
disease in another vascular bed), addressing most common
aspects from a diversity of complex clinical scenarios encountered
in clinical practice. Finally, major gaps in evidence are identified,
which may hopefully stimulate new research.
These guidelines are the result of a close collaboration between
physicians from many different areas of expertise: cardiology, vas-
cular surgery, vascular medicine/angiology, neurology, radiology,
etc., who have worked together with the aim of providing the
medical community with the data to facilitate clinical decision
making in patients with PAD.
3. General aspects
This section covers the epidemiology of PAD and associated risk
factors, as well as aspects of diagnosis and treatment common to
all specific vascular sites.
3.1 Epidemiology
The epidemiology of LEAD has been investigated in many
countries, including several in Europe. In a recent study in a popu-
lation aged 60–90 years in Sweden, the prevalence of LEAD was
18% and that of intermittent claudication was 7%.3 Typically,
one-third of all LEAD patients in the community are symptomatic.
The prevalence of critical limb ischaemia (CLI) is very much less—
0.4% in those over 60 years of age in the Swedish study.3 The esti-
mated annual incidence of CLI ranges from 500 to 1000 new cases
per 1 million population, with a higher incidence among patients
with diabetes.
The frequency of LEAD is strongly age related: uncommon
before 50 years, rising steeply at older ages. In a recent study in
Germany the prevalence of symptomatic and asymptomatic
LEAD in men aged 45–49 years was 3.0%, rising to 18.2% in
those aged 70–75 years. Corresponding rates for women were
2.7% and 10.8%.4 Prevalence rates between men and women are
inconsistent. There is, however, some suggestion of an equili-
bration between the sexes with increasing age. Incidence rates
are less often reported, but also show a strong relationship with
age. In the Framingham Study, the incidence of intermittent claudi-
cation in men rose from 0.4 per 1000 aged 35–45 years to 6 per
1000 aged 65 years and older.5 The incidence in women was
around half that in men, but was more similar at older ages.
The annual incidence of major amputations is between 120 and
500 per million in the general population, of which approximately
equal numbers are above and below the knee. The prognosis for
such patients is poor. Two years following a below-knee amputa-
tion, 30% are dead, 15% have an above-knee amputation, 15% have
a contralateral amputation, and only 40% have full mobility.6
Future trends in the epidemiology of LEAD are difficult to
predict due to changes in risk factors in the population, especially
tobacco smoking and diabetes, and due to the increased survival
from CAD and stroke, allowing LEAD to become manifest.
Limited evidence on trends during the past few decades has
suggested a decline in the incidence of intermittent claudication.
Table 2 Levels of evidence
Level of 
Evidence A 





Data derived from a single randomized 
clinical trial 
or large non-randomized studies. 
Level of 
Evidence C 
Consensus of opinion of the experts and/
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In 50-year-old Icelandic men the incidence decreased from 1.7 per
1000 in 1970 to 0.6 per 1000 in 1984,7 whereas in the Framingham
Study, the incidence decreased from 282 per 100 000 person-years
in 1950–1959 to 225 per 100 000 person-years in 1990–1999.8
In the Rotterdam Study of elderly people over 55 years of age, a
reduction in lumen diameter of the right internal carotid artery
from 16% to 49% was found in 3%, whereas severe stenosis
(≥50% reduction) was found in 1.4%.9 Likewise in the Tromso
Study of the general population over 50 years of age, the preva-
lence of carotid stenosis was 4.2% in men, which was significantly
higher than in women (2.7%) (P ¼ 0.001).10 Minor degrees of ste-
nosis are much more common. In the Cardiovascular Health Study
in subjects .65 years of age, 75% of men and 62% of women had
carotid plaques,11 and in the Framingham Study in men aged 75
years, .40% had stenosis .10%.8
Renal artery disease has been found frequently in post-mortem
studies, but evidence on prevalence in the general population is
limited. In the Cardiovascular Health Study of an elderly population
with mean age 77 years, the prevalence of renal artery disease,
defined as stenosis reducing arterial diameter by ≥60% or occlu-
sion, was 9.1% in men and 5.5% in women.12 However, much infor-
mation on the prevalence of renal artery disease has been derived
from studies of patients undergoing coronary angiography or
abdominal aortography in which the renal arteries have been
imaged. A systematic review of such studies found that between
10% and 50% of patients had renal artery stenosis (RAS) depending
on the risk group being examined.13 Owing to the selection of
patients for such studies, the prevalences were likely to be much
higher than those found in the general population.
Chronic symptomatic mesenteric artery disease is found rarely
in clinical practice although at times is under/misdiagnosed. It
accounts for only 5% of all intestinal ischaemic events and is
often severe, even fatal. The prevalence of asymptomatic mesen-
teric artery disease in the general population is not well estab-
lished. In patients with atherosclerotic disease at other sites,
atherosclerosis in the mesenteric arteries may be relatively
common: in patients with LEAD and renal artery disease, 27% of
patients had ≥50% stenosis in a mesenteric artery.14
Atherosclerosis occurs much less frequently in the arteries of
the upper extremity compared with the lower extremity. The sub-
clavian artery is often affected. In a study using data from four
cohorts in the USA, the prevalence of subclavian artery stenosis
in the general population was 1.9%, with no significant difference
between the sexes.15 Prevalence increased with age from 1.4% in
those ,50 years of age to 2.7% in those .70 years. Subclavian
stenosis was defined in this study as an inter-arm pressure differ-
ence of ≥15 mmHg, but, using angiography as the gold standard,
the sensitivity of this definition has been shown to be only
50% and specificity 90%. Thus the true prevalence of subclavian
artery stenosis may be much higher than that observed in the
cohorts. The majority of these cases are asymptomatic.
Given the common aetiology of peripheral atherosclerosis
occurring at different vascular sites, the presence of disease at
one site increases the frequency of symptomatic and asymptomatic
disease at another. The degree of concordance observed between
sites is, however, dependent on the methods of diagnosis and on
the selected population. From a clinical perspective, such findings
indicate the need for a heightened awareness of the possibility of
atherosclerotic disease occurring at sites other than the presenting
one. This is especially so in the elderly in whom the degree of
overlap of CAD, cerebrovascular disease, and LEAD is particularly
high.
3.2 Risk factors
Risk factors for PAD are similar to those important in the aetiology
of CAD and are the typical risk factors for atherosclerotic disease.
These include the traditional risk factors: smoking, dyslipidaemia,
diabetes mellitus, and hypertension. However, for some peripheral
artery sites the evidence linking these factors to the development
of disease is limited. Also, specific risk factors could be more
important for the development of disease at certain sites, but
there are few comparative studies.
In LEAD, cigarette smoking has been shown consistently in
several epidemiological studies to be an important risk factor
and to be dose dependent.16,17 Smoking would appear to be a
stronger risk factor for LEAD than for CAD and, in most
studies, patients with claudication have had a history of smoking
at some point in their lives. Smoking cessation is associated with
a rapid decline in the incidence of claudication, which equates to
that in non-smokers after 1 year of stopping.7 Diabetes mellitus
is the other risk factor especially important in the development
of LEAD. This is certainly true for severe disease, notably gangrene
and ulceration, but for intermittent claudication the strength of
the association with diabetes may be comparable with that for
coronary heart disease. The association of diabetes with LEAD is
inconsistent on multivariable analysis, which includes other risk
factors, but it appears that the duration and severity of diabetes
affect the level of risk.16,17
Most epidemiological studies show an association between
hypertension and the presence of LEAD, although interpretation
of such findings is difficult because blood pressure is a component
in the definition of disease [the ankle–brachial index (ABI)] and
may also affect the degree of ischaemia and the occurrence of
symptoms. However, no association has been found between
increased blood pressure and claudication. In contrast, in the
Limburg PAOD study, hypertension was associated with an
increased relative risk of 2.8 for LEAD18 and in the Rotterdam
Study a low ABI (,0.90) was associated with both increased sys-
tolic and diastolic blood pressure.19
Most epidemiological studies have found that high total choles-
terol and low high-density lipoprotein (HDL) cholesterol are inde-
pendently related to an increased risk of LEAD. In the US
Physicians Health Study, the ratio of total/HDL cholesterol was
the lipid measure most strongly related to disease.20
For other factors associated with CVD, such as obesity, alcohol
consumption, and plasma homocysteine levels, the associations
with LEAD have been inconsistent. In recent years, particular
interest in haemostatic, rheological, and inflammatory markers,
such as plasma fibrinogen and C-reactive protein,20 has led to
studies that have shown independent associations with both the
prevalence and incidence of LEAD, although whether such associ-
ations are primarily the cause or the effect is not clearly known.
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In general, the risk factors for carotid stenosis are similar to
those for LEAD, although smoking, while commonly associated
with carotid disease, is not so dominant as with LEAD. Several
population-based studies have found in both symptomatic and
asymptomatic disease that the classic risk factors of smoking,
high low-density lipoprotein (LDL) cholesterol, low HDL choles-
terol, hypertension, and diabetes mellitus are associated with
higher risk in both men and women irrespective of age.9 –11 The
risk factors for carotid artery disease, however need to be distin-
guished from those for ischaemic stroke, which is not necessarily
related to stenosis in the carotid arteries.
Likewise, for atheromatous renal artery disease the pathogenesis
is similar to that seen in other vascular sites and, although the evi-
dence is limited, would appear to be associated with typical cardi-
ovascular risk factors.21 These include pre-existing high blood
pressure in which the hypertension is not necessarily a compli-
cation but may be a cause of the RAS and may partly explain
why in many patients revascularization may not lead to a reduction
in blood pressure.
In chronic mesenteric artery disease, the atheromatous lesions
normally occur in the proximal segments of the splanchnic arteries.
The frequency of diffuse atherosclerosis has not been well
described but would appear to occur mostly in patients with end-
stage renal disease (ESRD) or diabetes. The classic cardiovascular
risk factors appear to be important, although hypocholesterolae-
mia (rather than hypercholesterolaemia) may be a presenting
finding due to a patient’s chronic malnourished state.
Significant associations were found between both increasing age
and higher systolic blood pressure with the presence of upper
extremity artery disease (UEAD).15 Compared with never
smokers, the risks were increased in current and past smokers,
and the odds ratio (OR) of 2.6 for current smokers was the
highest of any risk factor, perhaps mirroring that found for
LEAD. While a higher HDL cholesterol level appeared to be pro-
tective, surprisingly no association was found between total
cholesterol and subclavian stenosis. Diabetes mellitus was also
not related, although in another study the prevalence of UEAD
was found to be slightly higher in diabetic compared with non-
diabetic patients.22 Interestingly, in the four cohort study, LEAD,
compared with CAD and cerebrovascular disease, was much
more strongly related to UEAD.15
3.3 General diagnostic approach
3.3.1 History
History of risk factors and known co-morbidities is mandatory.
Hypertension, dyslipidaemia, diabetes mellitus, smoking status, as
well as history of CVD must be recorded. Medical history should
include a review of the different vascular beds and their specific
symptoms:
† Family history of CVD.
† Symptoms suggesting angina.
† Any walking impairment, e.g. fatigue, aching, cramping, or pain
with localization to the buttock, thigh, calf, or foot, particularly
when symptoms are quickly relieved at rest.
† Any pain at rest localized to the lower leg or foot and its associ-
ation with the upright or recumbent positions.
† Any poorly healing wounds of the extremities.
† Upper extremity exertional pain, particularly if associated with
dizziness or vertigo.
† Any transient or permanent neurological symptom.
† History of hypertension or renal failure.
† Post-prandial abdominal pain and diarhoea, particularly if related
to eating and associated with weight loss.
† Erectile dysfunction.
This cannot be an exhaustive list, and a review of symptoms should
include all domains. It is important to emphasize that history is a
cornerstone of the vascular evaluation.
One should remember that many patients, even with advanced
disease, will remain asymptomatic or report atypical symptoms.
3.3.2 Physical examination
Although physical examination alone is of relatively poor sensi-
tivity, specificity, and reproducibility, a systematic approach is man-
datory. It must include at least:
† Measurement of blood pressure in both arms and notation of
inter-arm difference.
† Auscultation and palpation of the cervical and supraclavicular
fossae areas.
† Palpation of the pulses at the upper extremities. The hands must
be carefully inspected.
† Abdominal palpation and auscultation at different levels includ-
ing the flanks, periumbilical region, and the iliac regions.
† Auscultation of the femoral arteries at the groin level.
† Palpation of the femoral, popliteal, dorsalis pedis, and posterior
tibial sites.
† The feet must be inspected, and the colour, temperature, and
integrity of the skin, and the presence of ulcerations recorded.
† Additional findings suggestive of LEAD, including calf hair loss
and skin changes, should be noted.
Beyond their diagnostic importance, clinical signs could have a
prognostic value. A meta-analysis published in 2008 emphasized
the prognostic value of carotid bruit.23 People with carotid
bruits have twice the risk of myocardial infarction and cardiovascu-
lar death compared with those without. This predictive value can
be extended to other clinical signs, such as femoral bruit, pulse
abnormality in the lower extremity, or inter-arm blood pressure
asymmetry. All of these abnormalities can be an expression of sub-
clinical vascular disease.
3.3.3 Laboratory assessment
The aim of the laboratory assessment is to detect major risk
factors of CVD. The assessment should be performed according
to the ESC Guidelines on Cardiovascular Disease Prevention24




The ABI is a strong marker of CVD and is predictive of cardiovas-
cular events and mortality. Low ABI values (,0.90) are predictive
of atherosclerosis, such as CAD and carotid artery disease. A
reduced ABI has been associated in several studies with an
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increased risk of cardiovascular morbidity and mortality.26 Also a
very high ABI (.1.40) in relation to stiffened arteries is associated
with increased mortality.27 Recently, the ABI has been shown to be
a valid method of cardiovascular risk assessment in diverse ethnic
groups, independent of traditional and novel risk factors, as well as
other markers of atherosclerosis such as the coronary artery
calcium score.27 ABI is recommended as an office measurement
in selected populations considered at high risk of CVDs. When
performed with a handheld Doppler device, the measurement
remains inexpensive and minimally time consuming.
The use of ABI to diagnose LEAD is discussed in Section 4.5.2.1.
3.3.4.2 Duplex ultrasound
Duplex ultrasound (DUS) is now widely available for the screening
and diagnosis of vascular lesions. Initially, with continuous wave
Doppler, severe stenoses were identified and quantified mainly
by the peak systolic velocities. Nowadays, DUS includes B-mode
echography, pulsed-wave Doppler, colour Doppler, and power
Doppler in order to detect and localize vascular lesions and quan-
tify their extent and severity.
By detecting subclinical artery disease, DUS provides relevant
information regarding cardiovascular risk assessment. B-mode
ultrasound is also a robust technique for the measurement of
the intima–media thickness (IMT), which has been studied
(mostly in the carotid arteries) and validated in several epidemio-
logical and interventional studies as a marker of atherosclerotic
burden in individuals and a predictor of cardiovascular morbidity
and mortality. Further, DUS allows a complete vascular evaluation
of the different beds and is often the first step in the clinical
management. New techniques, such as B-flow imaging or live three-
dimensional (3D) echography, as well as the use of ultrasound con-
trast agents, will further improve the performance of DUS.
3.3.5 Angiography
In the past, digital subtraction angiography (DSA) was the gold
standard of vascular imaging. Given its invasive characteristics,
this method has now been replaced by other effective non-invasive
diagnostic methods and is used almost exclusively during endovas-
cular procedures.
3.3.6 Computed tomography angiography
The introduction of multidetector computed tomography (MDCT)
has shortened the examination time and reduced motion and res-
piration artefacts while imaging the vessels and organs. The use of
computed tomography angiography (CTA) is not recommended
for screening purposes due to the high doses of radiation used,
potential contrast nephrotoxicity, and the lack of data demonstrat-
ing the effect of screening with CT.
When CTA is used for diagnostic purposes, nephrotoxicity can
be limited by minimizing the volume of contrast agents and ensur-
ing adequate hydration before and after imaging. The potential
benefit of acetylcysteine to limit nephrotoxicity is uncertain.
3.3.7 Magnetic resonance angiography
High-performance scanning is used during magnetic resonance
angiography (MRA) with a high signal–noise ratio and rapid data
acquisition. Morphological and functional studies require at least
a 1.0 Tesla system. In order to increase the resolution, special
phased-array surface coils are placed directly on the body, which
provide a homogeneous magnetic field over a large area.
Absolute contraindications include cardiac pacemakers,
implantable cardioverter defibrillators, neurostimulators, cochlear
implants, first-trimester pregnancy, and severe renal failure [glo-
merular filtration rate (GFR) ,30 mL/min per 1.73 m2]. Pacing
systems suitable for magnetic resonance imaging (MRI) have
been developed. Claustrophobia, metallic foreign objects, and
second- or third-trimester pregnancy are regarded as relative
contraindications.
Time-of-flight angiography and phase-contrast angiography,
without intravenous contrast, can be used to image the vascular
bed. Development of the ‘Angiosurf’ and ‘Bodysurf’ techniques28,29
has been a breakthrough in imaging. Based on the ‘Angiosurf’ MRA
approach, a fairly comprehensive combined protocol can be used,
which accomplishes the depiction of the head, thoracic, and all per-
ipheral arteries from the carotids to the ankles.30,31
Detailed descriptions of CTA and MRA are provided in
Appendix 1 (available online at www.escardio.org/guidelines).
3.4 Treatment—general rules
Patient management should include lifestyle modification,
focusing on smoking cessation, daily exercise (30 min/day),
normal body mass index (≤25 kg/m2), and a Mediterranean
diet.24 Pharmacological treatment can be added for blood
pressure control and a lipid-lowering treatment to achieve LDL
cholesterol ,2.5 mmol/L (100 mg/dL) with an option of
,1.8 mmol/L (,70 mg/dL) if feasible. In diabetic patients,
glucose control should be obtained, with the target glycated
haemoglobin (HbA1c) ,7%. Site-dependent therapy and revascu-
larization strategy are discussed in the respective sections. It must
be emphasized that the management of patients with PAD should
always be decided after multidisciplinary discussion, also including
(depending on lesion site) specialists beyond the area of cardio-
vascular medicine, e.g. neurologists or nephrologists.
3.4.1 Smoking cessation
Smoking is an important risk factor for PAD.32 In the general
population smoking increased the risk of LEAD between two-
and six-fold.16 Current smokers with LEAD also have an
increased risk of amputation, and are at increased risk of post-
operative complications and mortality.33 Smokers should be
advised to quit smoking and be offered smoking cessation pro-
grammes. Nicotine replacement therapy and/or bupropion or var-
enicline can facilitate cessation in patients with a high level of
nicotine dependence, which can be estimated by the Fagerström’s
questionnaire or biomarkers such as exhaled carbon monoxide
concentrations.34 All three medications are safe to use in patients
with CVD.35
3.4.2 Lipid-lowering drugs
Statins reduce the risk of mortality, cardiovascular events, and
stroke in patients with PAD with and without CAD. In the
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Heart Protection Study, 6748 participants had PAD; at 5-year
follow-up, simvastatin caused a significant 19% relative reduction
and a 6.3% absolute reduction in major cardiovascular events inde-
pendently of age, gender, or serum lipid levels.36 All patients with
PAD should have their serum LDL cholesterol reduced to
,2.5 mmol/L (100 mg/dL), and optimally to ,1.8 mmol/L
(,70 mg/dL), or ≥50% LDL cholesterol reduction when the
target level cannot be reached.24,25
3.4.3 Antiplatelet and antithrombotic drugs
The Antithrombotic Trialists’ Collaboration meta-analysis com-
bined data from 42 randomized studies of 9706 patients with
intermittent claudication and/or peripheral arterial bypass or
angioplasty. The incidence of vascular death, non-fatal myocardial
infarction, and non-fatal stroke at follow-up was significantly
decreased, by 23%, by antiplatelet drugs.37 Low-dose aspirin
(75–150 mg daily) was at least as effective as higher daily
doses. The efficacy of clopidogrel compared with aspirin was
studied in the randomized Clopidogrel versus Aspirin in Patients
at Risk for Ischaemic Events (CAPRIE) trial, including a subgroup
of 6452 patients with LEAD.38 At 1.9-year follow-up, the annual
combined incidence of vascular death, non-fatal myocardial infarc-
tion, and non-fatal stroke in the LEAD group was 3.7% and 4.9%,
respectively, in the clopidogrel and aspirin groups, with a signifi-
cant 23.8% decrease with clopidogrel. These benefits appeared
higher than in patients enrolled for CAD or stroke. The small
benefits of dual antiplatelet therapy do not justify its recommen-
dation in patients with LEAD due to an increased bleeding
risk.39,40
3.4.4 Antihypertensive drugs
Arterial hypertension in patients should be controlled adequately
according to the current ESC/European Society of Hypertension
guidelines.41 In general, target blood pressures of ≤140/
90 mmHg are recommended, and ≤130/80 mmHg in patients
with diabetes or chronic kidney disease. However, the latter
target has recently been contested.42
Treatment with angiotensin-converting enzyme (ACE) inhibitors
has shown a beneficial effect beyond a blood pressure decrease in
high-risk groups. In the Heart Outcomes Prevention Evaluation
(HOPE) trial, ACE inhibitor treatment with ramipril significantly
reduced cardiovascular events by 25% in patients with sympto-
matic PAD without known low ejection fraction or heart
failure.43 The ONTARGET trial showed equivalence of telmisartan
to ramipril in these patients.44
Importantly, b-blockers are not contraindicated in patients with
LEAD. A meta-analysis of 11 randomized controlled studies found
that b-blockers did not adversely affect walking capacity or symp-
toms of intermittent claudication in patients with mild to moderate
LEAD.45 At 32-month follow-up of 490 patients with LEAD and
prior myocardial infarction, b-blockers caused a 53% significant
independent relative decrease in new coronary events.46 Consider-
ing the cardioprotective effects of a low-dose, titrated b-blocker
regimen in the perioperative setting, b-blockers are recommended
in patients scheduled for vascular surgery according to the ESC
guidelines.47
4. Specific vascular areas
4.1 Extracranial carotid and vertebral
artery disease
4.1.1 Carotid artery disease
4.1.1.1 Definition and clinical presentations
In the Western world, ischaemic stroke has a major public health
impact as the first cause of long-term disability and the third
leading cause of death. Stroke mortality ranges from 10% to
30%, and survivors remain at risk of recurrent neurological and
cardiac ischaemic events. The risk of stroke and transient ischaemic
attacks (TIAs), defined in most studies as transient neurological
deficits usually lasting 1–2 h and no longer than 24 h, increases
with age. Major risk factors for stroke include hypertension,
hypercholesterolaemia, smoking, diabetes, cerebrovascular
Recommendations in patients with PAD: general
treatment
Recommendations Classa Levelb Ref c
All patients with PAD who 
smoke should be advised to 
stop smoking.
I B 48
All patients with PAD should 
have their LDL cholesterol 
lowered to <2.5 mmol/L
(100 mg/dL), and optimally 
to <1.8 mmol/L (70 mg/dL), or 
≥ 50% when the target level 
cannot be reached.
I Cd -
All patients with PAD should 
have their blood pressure 
controlled to ≤140/90 mmHg.
I A 41
ß-Blockers are not 
contraindicated in patients 
with LEAD, and should be 
considered in the case of 
concomitant coronary artery 
disease and/or heart failure.
IIa B 46, 47
Antiplatelet therapy is 
recommended in patients with 
symptomatic PAD.
I Cd 37
In patients with PAD and 
diabetes, the HbA1c level 
should be kept at ≤6.5%.  
I Cd -
In patients with PAD, a 
multidisciplinary approach is 






dEvidence is not available for all sites. When evidence is available,
recommendations specific for the vascular site are presented in the respective
sections.
HbA1c ¼ glycated haemoglobin; LDL ¼ low-density lipoprotein;
LEAD ¼ lower extremity artery disease; PAD ¼ peripheral artery disease.
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disease, atrial fibrillation, and other cardiac conditions that increase
the risk for embolic complications. Large artery atherosclerosis,
and specifically internal carotid artery stenosis, accounts for
20% of all ischaemic strokes.49 Carotid artery stenosis is con-
sidered symptomatic in the presence of TIA or stroke affecting
the corresponding territory within the previous 6 months.50,51 In
the vast majority of cases, carotid artery stenosis is caused by
atherosclerosis. Rare aetiologies include radiation therapy, vasculi-
tis, dissection, or fibromuscular dysplasia.
For the purpose of these guidelines, the term carotid artery ste-
nosis refers to a stenosis of the extracranial portion of the internal
carotid artery, and the degree of stenosis is according to the
NASCET criteria (see online Appendix 2).
In the North American Symptomatic Carotid Endarterectomy
Trial (NASCET), the risk of recurrent ipsilateral stroke in patients
with symptomatic carotid artery stenosis treated conservatively
was 4.4% per year for 50–69% stenosis and 13% per year for
.70% stenosis.52 In patients with asymptomatic carotid artery ste-
nosis .60%, the risk of stroke is 1–2% per year.53,54 However,
the risk may increase to 3–4% per year in elderly patients or in the
presence of contralateral carotid artery stenosis or occlusion, evi-
dence of silent embolization on brain imaging, carotid plaque het-
erogeneity, poor collateral blood supply, generalized inflammatory
state, and associated coronary or peripheral artery disease.1,52
Currently there are indications that the risk of stroke in patients




The decision to revascularize patients with carotid artery stenosis
is based on the presence of signs or symptoms related to the
affected carotid artery, the degree of internal carotid artery steno-
sis, and on patient age, gender, co-morbidities, and life expectancy.
Additional factors such as the presence of silent brain infarction in
the corresponding territory, microembolization on intracranial
Doppler, or the degree of stenosis progression may also be
taken into account.
Neurological evaluation is essential to differentiate asympto-
matic and symptomatic patients. All patients with neurological
complaints should be seen as soon as possible by a neurologist
since it may be challenging to determine whether symptoms are
related to a carotid artery stenosis. Manifestations of carotid
artery disease may be divided into hemispheric and/or ocular.
Hemispheric (cortical) ischaemia usually consists of a combination
of weakness, paralysis, numbness, or tingling (all affecting the same
side of the body) and contralateral to the culprit carotid artery.
Neuropsychological symptoms may also be present and may
include aphasia if the dominant hemisphere (usually left) is affected,
or neglect if the non-dominant hemisphere (usually the right, even
in most left-handed individuals) is affected. Emboli to the retinal
artery may cause temporary or permanent partial or total blind-
ness in the ipsilateral eye. A temporary ocular deficit is called
amaurosis fugax. While neurological symptoms of carotid disease
are usually caused by distal embolization, they may seldom be
due to cerebral hypoperfusion, either transient (‘low-flow TIA’)
or permanent (haemodynamic stroke).
4.1.1.2.2 Imaging
Urgent imaging of the brain and supra-aortic vessels is mandatory
in all patients presenting with TIA or stroke. While CT scan is
widely available and allows for a differentiation between ischaemic
and haemorrhagic stroke, MRI is more sensitive in the detection of
brain ischaemia.
The risk of recurrent TIA or stroke in the first month is 10–
30%.57 In patients with carotid artery stenosis, imaging conveys
important information such as the degree of carotid artery
stenosis, carotid plaque morphology, the presence of intracranial
disease, intracranial collateral circulation, asymptomatic embolic
events, or other intracranial pathologies.
DUS is commonly used as the first step to detect extracranial
carotid artery stenosis and to assess its severity. The peak systolic
velocity measured in the internal carotid artery is the primary vari-
able used for this purpose; secondary variables include the end-
diastolic velocity in the internal carotid artery as well as the ratio
of peak systolic velocity in the internal carotid artery to that in
the common carotid artery.58 Although DUS evaluation may be
hampered by severe plaque calcifications, tortuous vessels,
tandem lesions, and slow turbulent flow in subtotal stenoses, this
imaging modality allows for a reliable estimation of the degree of
the stenosis as well as for the assessment of plaque morphology
in the hands of an experienced investigator.
The advantages of CTA and MRA include the simultaneous
imaging of the aortic arch, the common and internal carotid arteries
in their totality, the intracranial circulation, as well as the brain par-
enchyma. MRA is more time-consuming than CTA but does not
expose patients to radiation, and the used contrast agents are far
less nephrotoxic. CTA offers excellent sensitivity and specificity
for the detection of carotid artery stenosis; however, the presence
of severe plaque calcification may lead to overestimation of the
degree of stenosis. In a systematic review and meta-analysis, no
major difference was found between DUS, MRA, and CTA for the
detection of a significant carotid artery stenosis.59 In order to
improve the accuracy of the diagnosis, the use of two imaging mod-
alities prior to revascularization is suggested. DSA may be required
for diagnostic purposes only in selected cases (e.g. discordant non-
invasive imaging results, additional intracranial vascular disease). In
patients with severe asymptomatic carotid artery stenosis, imaging
of the brain to detect asymptomatic embolic events and a transcra-
nial Doppler for emboli detection may be considered.
Recommendation for evaluation of carotid artery
stenosis
Recommendations Classa Levelb Ref c
DUS, CTA, and/or MRA are 






CTA ¼ computed tomography angiography; DUS ¼ duplex ultrasonography;
MRA ¼ magnetic resonance angiography.
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The overall benefit of aspirin to prevent cardiovascular events in
patients with atherosclerosis have been presented earlier
(Section 3.4.3). Although, the use of antiplatelet agents has not
been specifically addressed in patients with carotid artery disease
(i.e. carotid plaques), low-dose aspirin (or clopidogrel in case of
aspirin intolerance) should be administered to all patients with
carotid artery disease irrespective of symptoms. The effectiveness
of statins in patients with symptomatic cerebrovascular disease is
well proven, irrespective of the initial cholesterol concentration.
The Stroke Prevention by Aggressive Reduction in Cholesterol
Levels (SPARCL) study evaluated the results of high-dose
atorvastatin (80 mg/day) vs. placebo in 4731 patients with TIA or
stroke. Patients allocated to atorvastatin had a significant 26% rela-
tive risk reduction of the primary endpoint of fatal and non-fatal
stroke at 5 years.60 Among 1007 patients with carotid artery ste-
nosis enrolled in the trial, the benefit of statin therapy was even
more pronounced, with a 33% reduction of stroke, a 43%
reduction of major coronary events, and a 56% reduction of
carotid revascularization procedures at 5 years.61
4.1.1.3.2 Surgery
The benefits of carotid endarterectomy (CEA) over medical man-
agement in randomized trials were conveyed by low perioperative
complication rates [e.g. a stroke and death rate of 5.8% in
NASCET52 and of 2.7% in the Asymptomatic Carotid Athero-
sclerosis Study (ACAS)53] achieved by high-volume surgeons in
low-risk patients.
Temporary interruption of cerebral blood flow during CEA can
cause haemodynamic neurological deficits. This can potentially be
avoided by using a shunt. Currently there is insufficient evidence to
support or refute the use of routine or selective shunting as well
as perioperative neurological monitoring during CEA. As suggested
by a Cochrane review of seven trials, CEA using a patch (either pros-
thetic or vein based) may reduce the risk of restenosis and neurologi-
cal events at follow-up compared with primary closure.62 A more
recent randomized trial confirmed the lower restenosis rate associ-
ated with the patch, but could not find any difference in perioperative
complications.63 Usually, CEA is performed using a longitudinal arter-
iotomy. However, CEA with arterial eversion implies a transverse
arteriotomy and reimplantation of the internal carotid artery on
the common carotid artery. A Cochrane analysis on this subject
suggested that CEA with eversion may be associated with a lower
risk of (sub)acute occlusion and restenosis than conventional CEA,
but no difference in clinical events was detected.64
For decades it has been debated whether local anaesthesia is
superior to general anaesthesia for CEA. The randomized
General Anaesthesia versus Local Anaesthesia for Carotid
Surgery (GALA) trial including 3526 patients showed no difference
in terms of perioperative death, stroke, or myocardial infarction
between general (4.8%) and local (4.5%) anaesthesia.65
All patients undergoing CEA should receive perioperative
medical management according to proper cardiovascular risk
assessment. Low-dose aspirin is efficacious to reduce perioperative
stroke.37,52,54,66 There is no clear benefit of dual therapy or high-
dose antiplatelet therapy in patients undergoing CEA.
Technical aspects of CEA are addressed in Appendix 2.
4.1.1.3.3 Endovascular techniques
Carotid artery stenting (CAS) is a revascularization option less inva-
sive than CEA. It is performed under local anesthaesia, avoids neck
dissection with the consequent risk of peripheral nerve damage, and
is less painful. Although patients at high risk for surgery are not well
defined, CAS is frequently advocated for patients at increased car-
diopulmonary risk or with unfavourable neck anatomy, restenosis
after CEA, prior neck dissection or radiation therapy, as well as in
the presence of carotid artery stenosis difficult to access (i.e. high
internal carotid or low common carotid artery lesions).
The optimal anticoagulation regimen for CAS remains unknown.
Periprocedure unfractionated heparin is commonly used. Dual
antiplatelet therapy with aspirin and clopidogrel (or ticlopidine)
is recommended. Two small, randomized trials comparing aspirin
alone with double antiplatelet therapy for CAS were terminated
prematurely due to high rates of stent thrombosis and neurological
events in the aspirin-alone group.67,68
In patients with proven intolerance to dual antiplatelet therapy,
CEA should be preferred to CAS. Newer antiplatelet agents such
as prasugrel or ticagrelor have not yet been adequately tested in CAS.
4.1.1.3.4 Operator experience and outcomes of carotid artery stenting
While comparing the results of CAS and CEA, it should be acknowl-
edged that CAS gained maturity more recently than CEA, and that
the endovascular technique is evolving rapidly. Overall, available evi-
dence supports the notion that experience does play a major role in
CAS outcomes. The benefit is probably conveyed by optimal pro-
cedure management and appropriate patient selection. In this
respect, several CAS vs. CEA trials have been criticized for the insuf-
ficient endovascular experience required and for the possibility of
treating patients with CAS under proctoring conditions.69
More detailed information on the importance of operator
experience in CAS is provided in Appendix 2.
4.1.1.3.5 Embolic protection devices
The use of embolic protection devices (EPDs) during CAS remains
controversial. At present, only two very small, randomized studies
have evaluated CAS with vs. without EPDs, and failed to prove an
improved clinical outcome with the use of the devices.70,71
Opposing these results, two systematic reviews showed a
reduction in neurological events associated with protected
CAS.72,73 A benefit from EPDs was also suggested from a
large-scale prospective registry documenting an in-hospital death
or stroke rate of 2.1% among 666 patients undergoing CAS with
adjunctive EPD and of 4.9% in the group of patients (n ¼ 789)
treated without EPDs (P ¼ 0.004).74 In the same study, the use
of EPDs was identified in multivariable analysis as an independent
protective factor for this endpoint (adjusted OR 0.45, P ¼
0.026). Importantly, the complication rate associated with the
use of EPD appears to be low (,1%).75
In contrast, secondary analyses from two randomized CAS vs.
CEA trials reported a lack of benefit from EPD use during CAS.
In the SPACE trial, the rate of 30-day ipsilateral stroke or death
after CAS was 8.3% among 145 patients treated with EPDs and
6.5% in 418 patients treated without EPDs (P ¼ 0.40).76 In a sub-
study of the ICSS trial, new diffusion-weighted MRI lesions after
CAS were observed in 38 (68%) of 56 patients who had stenting
with EPDs and in 24 (35%) of 68 patients who had unprotected
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stenting [OR 3.28, 95% confidence interval (CI) 1.50–7.20; P ¼
0.003].77 Importantly, the use of EPDs in both trials was left to
the discretion of the operator. The best results for CAS so far
in randomized trials—for both symptomatic and asymptomatic
patients—have been obtained in studies that mandated embolic
protection with a single device and in which operators were
trained in the use of the specific device [Stenting and Angioplasty
with Protection in Patients at High Risk for Endarterectomy (SAP-
PHIRE)78 and CREST,79 as detailed below]. Finally, recent registry
data suggest that proximal occlusion systems may be useful in
embolic protection.80
4.1.1.4 Management of carotid artery disease
The management of carotid artery disease is summarized in
Figure 1.
Recommendations for embolic protection in patients
undergoing CAS
Recommendations Classa Levelb Ref c
Dual antiplatelet therapy 
with aspirin and clopidogrel 
is recommended for patients 
undergoing CAS.
I B 67, 68
The use of EPDs may be 











Management of carotid artery disease
Recent (<6 months) symptoms of stroke/TIA
Imaging of carotid artery





































Imaging of carotid artery
disease by Duplex ultrasound,
CTA and/or MRA
1 :  The management of symptomatic carotid artery disease should be decided as 
 soon as possible (<14 days after onset of symptoms)
2 :  After multidisciplinary discussion including neurologists
3 :  BMT = best medical therapy
Figure 1 Algorithm for the management of extracranial carotid artery disease. CTA ¼ computed tomography angiography; MRA ¼ magnetic
resonance angiography; TIA ¼ transient ischaemic attack.
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4.1.1.4.1 Asymptomatic carotid artery disease
4.1.1.4.1.1 Surgery
A total of 5233 patients with asymptomatic carotid artery
disease were enrolled in randomized multicentre trials compar-
ing CEA with medical management.53,54,66,81 After 4657 patient-
years of follow-up, the randomized Asymptomatic Carotid
Atherosclerosis Study (ACAS) estimated the 30-month risk of
ipsilateral stroke in the case of carotid artery stenosis .60%
at 5.1% for patients who underwent CEA in addition to best
medical therapy (at that time) vs. 11.0% for those with best
medical therapy alone.53 The Asymptomatic Carotid Surgery
Trial (ACST) randomized 3120 asymptomatic patients to either
immediate CEA or indefinite deferral of CEA.54 The 5-year risks
were 6.4% vs. 11.8% for all strokes (absolute risk reduction
5.4%, P ¼ 0.0001), 3.5% vs. 6.1% for fatal or disabling stroke
(absolute risk reduction 2.6%, P ¼ 0.004), and 2.1% vs. 4.2% for
fatal strokes (absolute risk reduction 2.1%, P ¼ 0.006), respect-
ively. Combining perioperative events and strokes, net risks
were 6.9% vs. 10.9% at 5 years (gain 4.1%, 2.0–6.2) and 13.4%
vs. 17.9% at 10 years (gain 4.6%, 1.2–7.9).66 Medication was
similar in both groups; throughout the study, most patients were
on antithrombotic and antihypertensive therapy. Net benefits
were significant irrespective of the use of lipid-lowering therapy,
for men and women under the age of 75 years at entry. In the
three trials, the benefit was greater in men than in women, but
the number of women enrolled was low.
It can be concluded that CEA is beneficial in asymptomatic
patients (especially men) between 40 and 75 years of age with
.60% stenosis, if their life expectancy is .5 years and operative
mortality ,3%.66,70 –77,79,81 However, the absolute benefit of
revascularization in terms of stroke prevention is small (1–2%
per year), and those trials were performed prior to extensive
use of statins. Therefore, the benefit of revascularization on top
of optimal medical management should be reassessed.
4.1.1.4.1.2 Endovascular therapy
The results of eight CAS registries enrolling .1000 patients
have been published recently (Table 3).82 The registries included
.20 000 patients at high surgical risk, mainly asymptomatic. Pre-
and post-procedure neurological assessment and blinded event adju-
dication were required in most studies. Overall, the studies demon-
strated that death and stroke rates with CAS are in the range
expected in current recommendations for CEA even in patients at
high surgical risk, and that CAS results tend to improve over time.
So far, the randomized evidence for CAS in asymptomatic
patients is limited. While no study has compared endovascular
treatment with medical therapy, two trials (SAPPHIRE and
CREST) comparing CAS vs. CEA have also enrolled asymptomatic
patients (for details see Section 4.1.1.4.2.2).
4.1.1.4.2 Symptomatic carotid artery disease
It should be emphasized that neurological assessment and appropriate
treatment should be proposed as soon as possible after the index
event. At a very minimum patients need to be seen and treated
within 2 weeks, with important benefit of instituting medical treat-
ment88 and performing revascularization as soon as possible after
the onset of symptoms.89,90
4.1.1.4.2.1 Surgery
Pooled data from the NASCET, the European Carotid Surgery
Trial (ECST), and the Veterans Affairs Trial included .35 000
patient-years of follow-up in patients (28% women) with sympto-
matic disease.50,51,91,92 CEA increased the 5-year risk of ipsilateral
ischaemic stroke over medical therapy alone in patients with














CAPTURE83 2007 3500 Yes Yes Mandatory 14% Yes Yes 5.7% 6.3% 10.6% 4.9%
CASES-PMS84 2007 1493 Yes Yes Mandatory 22% Yes Yes 4.5% 5.0% NA NA
PRO-CAS85 2008 5341 No No 75% 55% 70% No 3.6%b NA 4.3%b 2.7%b
SAPPHIRE–W78 2009 2001 Yes Yes Mandatory 28% Noc Yes 4.0% 4.4% NA NA
Society for 
Vascular Surgery86
2009 1450 No No 95% 45% No No NA 5.7% NA NA
EXACT87 2009 2145 Yes Yes Mandatory 10% Yes Yes 4.1% NA 7.0% 3.7%
CAPTURE-287 2009 4175 Yes Yes Mandatory 13% Yes Yes 3.4% NA 6.2% 3.0%
Stabile et al.80 2010 1300 No No Mandatory 28% Yes No 1.4% NA 3.0% 0.8%
aIndependent pre- and post-procedural assessment by a neurologist.
bIn-hospital events.
cNeurological assessment performed by stroke-scale-certified staff member.
CAPTURE ¼ Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events; CASES-PMS ¼ Carotid Artery Stenting with Emboli Protection Surveillance Study;
CEC ¼ clinical event committee adjudication; D ¼ death; EPD ¼ embolic protection device; EXACT ¼ Emboshield and Xact Post Approval Carotid Stent Trial; MI ¼ myocardial
infarction; N ¼ number of patients; NA ¼ not available; PRO-CAS ¼ Predictors of Death and Stroke in Carotid Artery Stenting; S ¼ stroke; SAPPHIRE ¼ Stenting and
Angioplasty with Protection in Patients at High Risk for Endarterectomy.
Reproduced with permission from Roffi et al.82
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,30% stenosis (n ¼ 1746, absolute risk increase 2.2%, P ¼ 0.05).
CEA had no effect in patients with 30–49% stenosis (n ¼ 1429,
absolute risk reduction 3.2%, P ¼ 0.06) and had a small benefit
in patients with 50–69% stenosis (n ¼ 1549, absolute risk
reduction 4.6%, P ¼ 0.04). CEA was highly beneficial in patients
with .70% stenosis but with no near occlusion (n ¼ 1095, absol-
ute risk reduction 16.0%, P ,0.001; the number needed to treat to
prevent one ipsilateral stroke in 5 years was 6). In contrast, in
patients with a 99% stenosis (near occlusion) and sluggish ante-
grade flow (‘string-flow’) in the internal carotid artery, CEA did
not show any advantage over medical treatment.
A pooled analysis of the ESCT and NASCET trials (5893 patients
with 33 000 patient-years of follow-up) convincingly demonstrated
that carotid revascularization should be performed rapidly in symp-
tomatic patients with TIA or mild stroke. The number needed to
treat to prevent one ipsilateral stroke in 5 years was 5 for those
randomized within 2 weeks after the last ischaemic event vs. 125
for patients randomized after 12 weeks.93
In symptomatic patients, the benefit of surgery is clearly estab-
lished for patients with stenosis .70%, but no near occlusion,
and to a lesser degree in patients with stenosis 50–69%. It
should be underscored that medical therapy in these old trials
did not include the use of statins.
4.1.1.4.2.2 Endovascular therapy versus surgery
A total of six large-scale (i.e. enrolling .300 patients) clinical trials
comparing CEA and CAS have been published. The CAVATAS,94
EVA-3S,95 ICSS,96 and SPACE97 trials enrolled exclusively sympto-
matic patients. The SAPPHIRE98,99 and CREST79 trials included
both symptomatic and asymptomatic patients at high and conven-
tional risk for surgery, respectively.
In the CAVATAS study (504 symptomatic patients), performed
prior to the introduction of EPDs, most patients allocated to endo-
vascular therapy were treated with angioplasty alone. Only 26%
received a stent. There was no statistical difference in terms of
any stroke or death at 30 days between CEA and angioplasty
(9.9% vs. 10%).94 Despite higher restenosis rates in the endovascu-
lar arm, no difference in the rates of non-periprocedural ipsilateral
stroke was reported at 8-year follow-up.100
The SAPPHIRE study randomized symptomatic and asymptomatic
patients at high risk for surgery.98 All endovascular patients were sys-
tematically treated with the same stent and a protection device. The
trial was designed to prove non-inferiority of CAS and was termi-
nated prematurely because of slow enrolment. The primary endpoint
of the trial was the cumulative incidence of death, stroke, or myocar-
dial infarction within 30 days after the procedure or ipsilateral stroke
occurring between 31 days and 1 year. Among the 334 randomized
patients (29% symptomatic), the primary endpoint occurred in
12.2% in the CAS group and in 20.1% in the CEA group (P¼
0.053). The difference was driven mainly by the rate of myocardial
infarction (2.4% in the CAS group vs. 6.1% in the CEA group; P¼
0.10). No cranial nerve injury was observed in the CAS group, com-
pared with 5.3% in the CEA group. The durability of CAS was docu-
mented by a comparable cumulative percentage of major (1.3% for
CAS vs. 3.3% for CEA) and minor (6.1% for CAS vs. 3.0% for
CEA) ipsilateral strokes at 3 years and a low rate of repeat revascu-
larization during the same period (3.0% for CAS vs. 7.1% for CEA).99
The SPACE study randomized 1200 symptomatic patients.101 Left
at the discretion of the treating physician, EPDs were used in 27% of
the cases. The trial was prematurely stopped because of slow enrol-
ment and lack of funding. The incidence of ipsilateral stroke or death
at 30 days was the primary endpoint of the study and did not differ
between the groups. With an insufficient sample size, SPACE failed
to prove the non-inferiority of CAS with the pre-specified absolute
difference of 2.5% (P ¼ 0.09). Follow-up analysis showed no differ-
ence in the 2-year rate of adverse events between groups (8.8%
for CEA and 9.5% for CAS; P ¼ 0.62).102
The EVA-3S trial randomized 527 symptomatic patients with a ste-
nosis ≥60% to CAS or CEA.95 The primary endpoint was the cumu-
lative incidence of any stroke or death within 30 days after treatment.
Although not mandated, CAS without EPD protection was rapidly
halted because of excessive risk of stroke compared with those
with an EPD (OR 3.9, 95% CI 0.9–16.7).103 The trial was stopped
prematurely because of significant increased event rates in the CAS
arm (death or stroke 9.6% vs. 3.9% in the CEA arm; P ¼ 0.01).
Beyond 30 days, no difference in death or stroke rate was observed,
but at 4-year follow-up, the results of CEA were still more favourable
than those of CAS, driven by the periprocedural events.104
The ICSS study randomized 1710 symptomatic patients to CEA
or CAS (EPD use was not mandatory and protected CAS was per-
formed in 72% of patients). The primary endpoint was the 3-year
rate of fatal or disabling stroke. While follow-up is ongoing, an
interim safety analysis of events between randomization and 120
days reported an incidence of death, stroke, or periprocedural
myocardial infarction in favour of CEA, with an incidence of 8.5%
in the CAS group and 5.2% in the CEA group [hazard ratio (HR)
1.69, 95% CI 1.16–2.45; P ¼ 0.004].96 The difference was driven
mainly by a lower rate of non-disabling strokes in the CEA arm.
The CREST study was a multicentre, randomized controlled trial
(RCT) with the primary endpoint of periprocedural stroke, myocar-
dial infarction, or death, plus ipsilateral stroke up to 4 years. The
study was characterized by strict requirements in terms of endovas-
cular credentialing and a lead-in phase that included the treatment of
1541 patients with CAS that preceded the randomized enrolment.
Owing to slow enrolment, this study—initially designed for sympto-
matic patients—was then extended to include asymptomatic individ-
uals.79 The primary endpoint occurred in 7.2% of the CAS group
and in 6.8% of the CEA group (HR 1.11, 95% CI 0.81–1.51; P ¼
0.51). With respect to periprocedural death, stroke, or myocardial
infarction, no difference was observed, with an event rate of 5.2%
in the CAS group and 4.5% in the CEA group (P ¼ 0.38). Patients
randomized to CAS had more periprocedural strokes (HR 1.79,
95% CI 1.14–2.82; P ¼ 0.01), but they had fewer myocardial infarc-
tions (1.1% vs. 2.3%; 95% CI 0.26–0.94; P ¼ 0.03) compared with
those receiving CEA. The incidence of major periprocedural
strokes was low and not different between the two groups (0.9%
vs. 0.6%; P ¼ 0.52). Cranial nerve palsy occurred in 0.3% of patients
randomized to CAS and in 4.7% of those treated with CEA (HR
0.07, 95% CI 0.02–0.18; P ,0.0001). At 4 years, no difference in
rates of ipsilateral stroke after the periprocedural period was
observed (HR 0.94, 95% CI 0.50–1.76; P ¼ 0.85).
A meta-analysis of 13 randomized trials and including those
mentioned above involved 7484 patients, of which 80% had symp-
tomatic disease. Compared with CEA, CAS was associated with
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increased risk of any stroke (RR 1.45; 95% CI 1.06–1.99),
decreased risk of periprocedural myocardial infarction (RR 0.43;
95% CI 0.26–0.71), and non-significant increase in mortality (RR
1.40; 95% CI 0.85–2.33).105
4.1.2 Vertebral artery disease
4.1.2.1 Definition and natural history
The prevalence of vertebral artery (VA) disease due to athero-
sclerotic disease in the general population is unknown as this con-
dition often remains undiagnosed, because it is either
asymptomatic or due to neglected symptoms of vertebrobasilar
ischaemia.106 Approximately 20% of all ischaemic strokes are esti-
mated to involve the vertebrobasilar territory.107,108 Vertebrobasi-
lar stroke is primarily the result of an embolic process—most
frequently artery-to-artery embolism from the VA origin or cardi-
oembolism. On occasion, dissection, thrombotic, and low-flow
haemodynamic mechanisms may be involved.109 A significant ste-
nosis of the extracranial VA—mostly located at its origin—may
account for up to 20% of all vertebrobasilar strokes or TIAs.110
4.1.2.2 Imaging
Data on the accuracy of non-invasive imaging for the detection of
extracranial VA are limited and none of the studies has compared
different imaging modalities against contrast angiography. A recent
systematic review suggested that MRA offers better sensitivity and
specificity than DUS for extracranial VA stenosis.111 While CTA is
increasingly used for assessment of VA disease, this technique still
needs validation.111 Both MRA and CTA may be inadequate for
ostial VA lesions, especially in the presence of severe angulation
or tortuosity of the VA take-off. Despite those limitations, contrast
angiography is rarely used merely for diagnostic purposes.
4.1.2.3 Management of vertebral artery disease
The overall benefits of antiplatelet and statin therapy have been
presented earlier in these guidelines (Section 3.4.3). Although
there are no prospective studies evaluating different therapeutic
Recommendations for management of asymptomatic
carotid artery disease
Recommendations Classa Levelb Ref c
All patients with asymptomatic 
carotid artery stenosis should 
be treated with long-term 
antiplatelet therapy.
I B 52, 54, 66
All patients with asymptomatic 
carotid artery stenosis should 
be treated with long-term 
statin therapy.
I C -
In asymptomatic patients with 
carotid artery stenosis ≥60%, 
CEA should be considered 
as long as the perioperative 
stroke and death rate for 
procedures performed by 
the surgical team is <3% and 
the patient’s life expectancy 
exceeds 5 years.
IIa A 52, 54, 66
In asymptomatic patients 
with an indication for carotid 
revascularization, CAS may be 
considered as an alternative to 
CEA in high-volume centres 
with documented death or 
stroke rate <3%.




CAS ¼ carotid artery stenting; CEA ¼ carotid endarterectomy.
Recommendations for management of symptomatic
carotid artery disease
Recommendations Classa Levelb Ref c
All patients with symptomatic 
carotid stenosis should receive 
long-term antiplatelet therapy.
I A 37
All patients with symptomatic 
carotid stenosis should receive 
long-term statin therapy.
I B 60, 61
In patients with symptomatic 
70-99% stenosis of the 
internal carotid artery, CEA 
is recommended for the 
prevention of recurrent stroke.
I A
50, 51, 91, 
92
In patients with symptomatic 
50-69% stenosis of the internal 
carotid artery, CEA should 
be considered for recurrent 
stroke prevention, depending 
on patient-specific factors.
IIa A
50, 51, 91, 
92
In symptomatic patients 
with indications for 
revascularization, the 
procedure should be 
performed as soon as possible, 
optimally within 2 weeks of 
the onset of symptoms. 
I B 93
In symptomatic patients at 
high surgical risk requiring 
revascularization, CAS should 
be considered as an alternative 
to CEA.
IIa B 79, 99, 102
In symptomatic patients 
requiring carotid 
revascularization, CAS may be 
considered as an alternative to 
CEA in high-volume centres 
with documented death or 
stroke rate <6%.




CAS ¼ carotid artery stenting; CEA ¼ carotid endarterectomy.
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strategies in patients with VA disease, aspirin (or if not tolerated
clopidogrel) and statins should be administered in all patients, irre-
spective of symptoms. Asymptomatic VA disease does not require
intervention. In general, the need to intervene is tempered by the
fact that the posterior circulation is supplied by the confluence of
the two VAs, and a large proportion of patients remain asympto-
matic despite an occlusion of one VA. However, in patients with
recurrent ischaemic events under antiplatelet therapy or refractory
vertebrobasilar hypoperfusion, revascularization may be
considered.
Although surgery of extracranial VA stenosis has been per-
formed with low rates of stroke and mortality by surgeons with
extensive experience,112 in most centres the surgical approach
has been replaced by endovascular techniques. However, data
for VA revascularization are limited to retrospective and mainly
single-centre studies.
More information is provided in the online Appendix 2.
4.2 Upper extremity artery disease
4.2.1 Definition and clinical presentation
The subclavian artery and brachiocephalic trunk are the most
common locations for atherosclerotic lesions in the upper extre-
mities. However, UEAD can be caused by a number of conditions,
involving different levels of the upper extremity arterial system
(see online Appendix 3). The most common manifestation for sub-
clavian arterial occlusive disease is unequal arm pressures. A differ-
ence of ≥15 mmHg is highly suspicious for subclavian stenosis. It is
not uncommon to detect this occlusive disease in asymptomatic
patients. Nevertheless, when the subclavian or brachiocephalic
trunk becomes symptomatic, the clinical scenario can be diverse.
Subclavian steal syndrome due to flow reversal in the VA, which
is worsened by exercising the arm, can evoke symptoms of verteb-
robasilar insufficiency (dizziness, vertigo, blurred vision, alternating
hemiparesis, dysphasia, dysarthria, confusion, and loss of con-
sciousness, drop attacks, ataxia or other postural disturbances
including sensory and visual changes). Patients with coronary
bypass with an internal mammary artery can develop symptoms
of myocardial ischaemia as the manifestation of subclavian steal
syndrome. Brachiocephalic occlusive disease can also lead to
stroke related to the carotid and vertebral territories. Ischaemic
arm symptoms are characterized by crampy pain on exercise—
also referred to as arm claudication. In more severe cases—
especially in more distal disease—rest pain and digital ischaemia
with gangrene can develop.
4.2.2 Natural history
Little is known about the natural history of subclavian stenosis, but
the prognosis appears relatively benign. Only subclavian steal with
myocardial ischaemia in patients revascularized using the internal
mammary artery as well as symptomatic brachiocephalic athero-
sclerosis with stroke episodes can be considered as life-threatening
clinical conditions. However, any symptomatic subclavian occlusive
disease should be investigated and treated. Vertebrobasilar insuffi-
ciency related to subclavian artery stenosis can be recurrent even
after revascularization procedures. It can be explained by numer-
ous other conditions such as cardiac arrhythmias, or intracerebral
small vessel disease that can mimic symptoms of vertebrobasilar
insufficiency. The combination of proximal and distal arm occlusive
disease can present a clinical challenge, with poor prognosis for the
extremity.
4.2.3 Clinical examination
Clinical diagnosis of upper limb ischaemia is based on history and
physical examination including bilateral blood pressure measure-
ment and assessment of the axillary, brachial, radial, and ulnar
artery pulses. Auscultation is an important part of upper extremity
examination and should begin in the supraclavicular fossa. Signs and
symptoms, such as pulse deficit, arm pain, pallor, paraesthesia,
coldness, and unequal arm pressures, warrant further investigation
for occlusive artery disease of the upper limb. The Allen test
should be performed in patients in whom the radial artery is instru-
mented or harvested for coronary revascularization. Adequate col-
lateral flow via the ulnar artery is to be confirmed by this test.
4.2.4 Diagnostic methods
4.2.4.1 Duplex ultrasonography
The proximal location of subclavian arterial occlusive disease
makes DUS challenging. However, duplex scanning is of particular
value in differentiating occlusion from stenosis, in determining the
direction of the vertebral blood flow, and in screening for concur-
rent carotid artery stenosis. Subclavian steal can be present in the
absence of retrograde vertebral flow at rest. Dynamic examination
with cuff compression of the upper arm and consecutive hyperae-
mia after decompression can change the vertebral flow direction.
4.2.4.2 Computed tomography angiography
Upper limb atherosclerosis can be imaged in excellent detail using
CTA. To avoid misinterpretations, it is important to detect conge-
nital abnormalities, in order to define precisely the four vessels
perfusing the head. CTA should be analysed interactively, based
on a combination of axial images and post-processed views.
4.2.4.3 Magnetic resonance angiography
The use of MRI and contrast-enhanced MRA should also be con-
sidered because it enables acquisition of both functional and
Recommendations for revascularization in patients
with VA stenosis
Recommendations Classa Levelb
In patients with symptomatic extracranial 
VA stenosis, endovascular treatment may be 
considered for lesions ≥50% in the case of 
recurrent ischaemic events despite optimal 
medical management.
IIb C
Revascularization of an asymptomatic VA 
stenosis is not indicated, irrespective of the 




VA ¼ vertebral artery.
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morphological information. This information can be used to dis-
tinguish antegrade from retrograde perfusion. MRA can be com-
bined with special sequences to detect vessel wall oedema and
contrast enhancement after administration of intravenous contrast.
MRA can detect dilatation and stenosis of the supra-aortic vessels
that may be associated with both arteritis and atherosclerosis.
Assessment of antegrade and retrograde flow is particularly
helpful when steal syndrome is suspected. MRA is particularly
useful for follow-up studies.
4.2.4.4 Digital subtraction angiography
DSA is the gold standard in imaging. However, it is increasingly
being replaced by other imaging modalities, such as CTA and MRA.
4.2.5 Treatment
Control of the risk factors for atherosclerosis should be offered to
all patients with UEAD, including asymptomatic subjects, because
they are at increased risk of death.113
Revascularization is sometimes indicated in asymptomatic
patients, such as CAD patients with planned use of the internal
mammary artery for the coronary bypass grafting, or patients
with bilateral upper limb lesions to enable blood pressure
measurement.
In symptomatic patients endovascular and surgical treatment
options are available.
Neither acute results nor long-term patency rates have been
compared in randomized studies for the two techniques. The
risk of severe complications is low with both approaches, and in
particular the risk of vertebrobasilar stroke is rarely reported.
Atherosclerotic lesions of the upper extremities, mostly subclavian
lesions, are nowadays treated primarily by endovascular tech-
niques. The primary technical success rate is very high and
similar to that for surgical treatment. The less invasive nature of
endovascular treatment outweighs supposedly better long-term
results of surgical interventions.114
Ostial lesions should preferably be treated with
balloon-expandable stents because they can be placed more pre-
cisely than self-expanding stents. Furthermore, the ostial lesions
are more likely to be highly calcified, and in this situation the
higher radial force of balloon-expandable stents might be
beneficial.
Sixt et al.114 reported a primary success rate of 100% for treat-
ment of stenoses and 87% for occlusions. They also compared
stenting procedures with balloon angioplasty and found a trend
for an improved 1-year primary patency rate after stent-supported
angioplasty (89% vs. 79%). For occlusions, the primary patency rate
was 83%.
De Vries et al.115 reported an initial technical success rate of
100% for stenosis and 65% for occlusions. However devices and
the experience of the interventionists have since improved and
are associated with better results, including for treatment of occlu-
sions. The long-term clinical results in that study were favourable,
with a 5-year primary patency rate of 89%.
For subclavian artery occlusions, surgical reimplantation demon-
strated long durability with low operative mortality and morbidity
rates. Carotid–subclavian bypass with a prosthetic graft is a good
surgical alternative.116
Other extra-anatomical bypass modalities, such as axilloaxillary
and subclavian–subclavian, are considered the third surgical
choice for this pathology. The transthoracic approach is generally
reserved for patients with multivessel aortic and supraortic trunk
disease, which may preclude an extra-anatomical repair. The
latter surgical option is related to higher mortality and morbidity
when compared with transpositions or extra-anatomical
reconstructions.117
Some clinical or anatomical circumstances, such as old age, high
surgical risk, previous sternotomy, or calcified ascending aorta, can
preclude the transthoracic surgical approach. In these cases, an
extra-anatomical or endovascular approach can be applied.118
Nevertheless, no randomized trials have been performed to
compare different therapeutic options. Other therapies, including
prostanoid infusion and thoracocervical sympathectomy, may be
considered when revascularization is not possible.119
4.3 Mesenteric artery disease
4.3.1 Definition
Patients with mesenteric artery disease may be asymptomatic.120
Symptomatic mesenteric artery disease is an uncommon, poten-
tially underdiagnosed condition caused by fixed stenoses or occlu-
sion of at least two visceral arteries. Stenosis of one and even two
visceral vessels is usually well tolerated because of the abundant
collateral circulation between the coeliac trunk, the superior
mesenteric artery, and the inferior mesenteric artery—the latter
Recommendations for the management of upper
extremity artery disease
Recommendations Classa Levelb
Revascularization is indicated in symptomatic 
patients.
I C
When revascularization is indicated, an 
endovascular-first strategy is recommended 
in patients with atherosclerotic lesions of the 
upper extremities.
I C
Surgery should be considered after failed 
endovascular treatment in low-surgical-risk 
patients.
IIa C
Revascularization may be considered in 
asymptomatic patients with former or future 
mammary-coronary bypass or to monitor 
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being connected to branches of the internal iliac arteries. Athero-
sclerosis is the leading cause of mesenteric artery disease (95%).
Typically, patients affected by mesenteric artery disease have
diffuse atherosclerotic disease including CAD.120,121 Non-
atherosclerotic causes of mesenteric artery disease such as fibro-
muscular disease, Dunbar syndrome (compression of the coeliac
trunk by the arcuate ligament), and vasculitis will not be discussed.
4.3.2 Clinical presentation
Patients with mesenteric artery disease usually present with
abdominal angina, a clinical syndrome characterized by painful
abdominal cramps and colic occurring typically in the post-prandial
phase.121 Patients may suffer from ischaemic gastropathy, a
condition characterized by the fear of food, nausea, vomiting,
diarrhoea, malabsorption, and unintended progressive weight
loss.122,123 Acute mesenteric ischaemia may also be caused by
mesenteric artery thrombosis, with a grim prognosis.
4.3.3 Prevalence and natural history
The incidence of mesenteric artery disease in the general popu-
lation is 1 per 100 000 per year.124 In patients with known ather-
osclerotic disease, the prevalence of mesenteric artery disease may
range from 8% to 70%, and a .50% stenosis of more than one
splanchnic artery may be detected in up to 15% of cases.125 – 128
In patients with abdominal aortic aneurysm, aortoiliac occlusive
disease, and infrainguinal LEAD, a significant stenosis of at least
one of the three visceral arteries may be found in 40, 29, and
25% of cases, respectively.120 Predisposing conditions for the
development of mesenteric artery disease include arterial hyper-
tension, diabetes mellitus, smoking, and hypercholesterolaemia.
Untreated symptomatic mesenteric artery disease may lead to
starvation, bowel infarction, and death.
4.3.4 Diagnostic strategy
DUS has become the imaging method of choice for mesenteric
artery disease.129– 133 The diagnostic performance may be
improved by a post-prandial test, revealing increased velocity and
turbulences, which may seem trivial in a fasting patient. CTA and
gadolinium-enhanced MRA are useful initial tests for supporting
the clinical diagnosis of symptomatic mesenteric artery disease if
the results of DUS are inconclusive.134 –137 Recently, 24 h gastro-
intestinal tonometry has been validated as a diagnostic test to
detect splanchnic ischaemia and to guide treatment.138 Basically,
gastrointestinal tonometry measures gut intraluminal CO2. Intra-
luminal gut CO2 is elevated when local perfusion is compromised
based on the concept that in situations where gastrointestinal per-
fusion is reduced oxygen delivery falls below a critical level, result-
ing in anaerobic cellular metabolism that leads to local lactic
acidosis and generation of CO2.
Ischaemic colitis is frequently diagnosed by histology following
biopsy during bowel endoscopy. DSA is still considered the diag-
nostic gold standard, but its use is now limited to peri-
interventional imaging.139,140
4.3.5 Prognostic stratification
Five-year mortality in asymptomatic patients with mesenteric
artery disease is estimated at 40%, and up to 86% if all three
main visceral arteries are affected.120 Diffuse mesenteric artery
disease in asymptomatic subjects should be considered as a
marker of increased cardiovascular mortality, justifying aggressive
management of cardiovascular risk factors.
4.3.6 Treatment
Recent reports have suggested that endovascular therapy, with or
without stenting, may have a lower perioperative mortality rate than
open surgery for revascularization of mesenteric artery disease. Retro-
spective data from a US nationwide inpatient sample analysis (1988–
2006) including .22 000 patients suggested a lower mortality rate
after endovascular therapy compared with surgical bypass (3.7% vs.
13%, P , 0.01).142 In addition, bowel resection was less frequent in
the endovascular group than in the surgical group (3% vs. 7%, P ,
0.01). Bowel resection was, in general, associated with a high
in-hospital mortality rate [percutaneous transluminal angioplasty
(PTA)/stenting 25% and surgery 54%, respectively]. The lower
in-hospital mortality rates reported after angioplasty with or without
stenting indicate that this strategy should be proposed when possible.
Longitudinal data are needed to determine the durability of this
benefit. So far no randomized controlled data are available.
Symptom relief following revascularization is reported in up to
100% of cases, although restenosis after endovascular therapy
may be frequent (29–40%). Although no controlled data
support the strategy, dual antiplatelet therapy for 4 weeks post-
procedure, followed by long-term aspirin treatment, has become
the standard of care. DUS follow-up every 6–12 months is rec-
ommended. The use of drug-eluting stents, flared stent devices,
or drug-eluting balloons in conjunction with bare-metal stents
has not yet been evaluated in larger studies.
Recommendations for diagnosis of symptomatic
chronic mesenteric ischaemia
Recommendations Classa Levelb Ref c
DUS is indicated as the first-
line diagnostic test in patients 





When DUS is inconclusive, 






is indicated exclusively during 






CTA ¼ computed tomography angiography; DUS ¼ duplex ultrasonography;
MRA ¼ magnetic resonance angiography.
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4.4 Renal artery disease
Renal artery disease is increasingly related to atherosclerosis with
advancing age and prevalent hypertension, diabetes mellitus, renal
disease, aortoiliac occlusive disease, and CAD.151 In the elderly
population, atherosclerosis accounts for 90% of cases and
usually involves the ostium and proximal third of the main renal
artery and the perirenal aorta. Less frequent causes are fibromus-
cular dysplasia and arteritis. Screening angiography in potential
kidney donors indicates that RAS can be asymptomatic and may
be present in up to 3–6% of normotensive individuals.152
4.4.1 Clinical presentation
Major clinical signs of RAS include refractory hypertension, unex-
plained renal failure, and flash pulmonary oedema (Table 4). RAS
may cause or deteriorate arterial hypertension and/or renal
failure. Hypoperfusion of the kidney activates the renin–angioten-
sin–aldosterone system (RAAS), causing classic renovascular
hypertension, primarily in young patients with fibromuscular dys-
plasia.151,153 However, in patients with atherosclerosis, RAS may
induce an acute or subacute acceleration of a pre-existing essential
hypertension including flash pulmonary oedema usually in bilateral
kidney disease.151 The association between RAS severity and
ischaemic nephropathy154,155 has recently been challenged.156
The loss of filtration capacity of the kidney in RAS may be due
not only to hypoperfusion, but also to recurrent microembolism.
Renal failure may occur with severe bilateral RAS or unilateral
stenosis in a single functional kidney.
Kidney disease and renovascular disease promote CVD and
hypertension. Increased risk of CVD in atherosclerotic RAS
patients may result from activation of the RAAS and sympathetic
nervous systems, decreased GFR, or concomitant atherosclerosis
in other vascular beds.157 – 159 The prevalence of left ventricular
hypertrophy with RAS is 79% vs. 46% in patients with essential
hypertension, with a substantial impact on morbidity and
mortality.160 –162
4.4.2 Natural history
Data on progression of atherosclerotic RAS are inconsistent. More
recent studies show significant disease progression to high-grade
stenosis or occlusion in only 1.3–11.1% of patients, whereas
older studies documented occlusion rates up to 18% over 5
years.163 –166 After 2 years, 3, 18, and 55% of the kidneys had
lost their function in the case of unilateral stenosis, bilateral steno-
sis, and contralateral occlusion, respectively.167
4.4.3 Diagnostic strategy
Baseline diagnostic evaluation includes physical examination, exclu-
sion of other potential causes of secondary hypertension, and
ambulatory blood pressure measurement. In clinical situations in
which RAS is suspected, such as those listed in Table 4, renal
artery imaging should be considered.
DUS is the first-line screening modality for atherosclerotic RAS.
It can be applied serially to assess the degree of stenosis and phys-
iological patterns, such as flow velocities and vascular resistance.
Increased peak systolic velocity in the main renal artery associated
with post-stenotic turbulence is most frequently used to deter-
mine relevant RAS, and corresponds to ≥60% angiographic RAS
with a sensitivity and specificity of 71–98% and 62–98%, respect-
ively.168 –170 Several duplex criteria should be used to identify sig-
nificant (.60%) stenosis. These include imaging of intrarenal
interlobar or segmental arteries, including calculation of the side-
difference of the intrarenal resistance index, missing early systolic
peak, retarded acceleration, and increased acceleration time,
which are less specific and should be used to support the diagnosis
based on peak systolic velocity.171 – 173
Common pitfalls of DUS include failure to visualize the entire
renal artery and missing the highest peak systolic velocity during
spectral Doppler tracing. Accessory renal arteries are generally
not adequately examined or identified. The accuracy of DUS is
operator dependent.
Recommendations for the management of mesenteric
artery disease
Recommendations Classa Levelb Ref c
Mesenteric revascularization 
should be considered in 





In the case of revascularization, 
endovascular treatment should 






Table 4 Clinical situations where the diagnosis of RAS
should be considered
Clinical presentation
• Onset of hypertension before the age of 30 years and after 55 years 
• Hypertension with hypokalemia, in particular when receiving thiazide 
 diuretics
• Hypertension and abdominal bruit
• Accelerated hypertension (sudden and persistent worsening of 
 previously controlled hypertension) 
• Resistant hypertension (failure of blood-pressure control despite full 
 doses of an appropriate three-drug regimen including a diuretic)
• Malignant hypertension (hypertension with coexistent end-organ 
 damage, i.e. acute renal failure, flash pulmonary oedema, hypertensive 
 left ventricular failure, aortic dissection, new visual or neurological 
 disturbance, and/or advanced retinopathy)
• New azotemia or worsening renal function after the administration 
 of an angiotensin-converting enzyme inhibitor or an angiotensin II 
 receptor blocker
• Unexplained hypotrophic kidney
• Unexplained renal failure 
RAS ¼ renal artery stenosis.
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Both 3D MRA and multidetector CTA have demonstrated
equally high sensitivities (.90%) for detection of haemodynami-
cally significant stenoses, with excellent interobserver and inter-
modality agreement.174
Currently CTA provides higher spatial resolution than MRA and
may be more readily available; however, the requirement to use
iodinated contrast makes it an unattractive modality in patients
with impaired renal function.
Gadolinium-enhanced MRA provides excellent characterization
of the renal arteries, surrounding vessels, renal mass, and occasion-
ally renal function. It is less useful in patients with renal artery
stents because of artefacts. In addition, MRA tends to overestimate
the degree of luminal narrowing. A recent concern in the use of
gadolinium-enhanced MRI is nephrogenic systemic fibrosis, with
an incidence ranging from 1% to 6% for dialysis patients, and a
GFR ,30 mL/min was designated as a contraindication.175
In recent years measuring the translesional pressure gradient
with a dedicated pressure wire was proposed to identify a signifi-
cant RAS. A distal-to-the-lesion to aortic pressure ratio at rest of
,0.9 was linked to an upregulation of renin production.151 This
ratio correlates to a papaverine-induced hyperaemic systolic
pressure gradient of .21 mmHg.176 A dopamine-induced mean
pressure gradient of .20 mmHg predicted a beneficial blood
pressure response to renal stenting.177
DSA is generally limited to pre-angioplasty visualization and
quantification of the stenosis. It may also be considered in patients
with high clinical suspicion of RAS already scheduled for another
angiographic examination (e.g. coronary angiography) or in the
case of inconclusive non-invasive imaging.
4.4.4 Prognostic stratification
Among patients with ESRD, the life expectancy of those with RAS
is the poorest.179 However, life expectancy is also significantly
reduced in patients with RAS without ESRD.179 Two-year mor-
tality in patients with baseline serum creatinine concentrations
before revascularization of ,1.2 mg/dL, 1.2–2.5 mg/dL, and
.2.5 mg/dL were 5, 11, and 70%, respectively.180 More than
80% of patients die due to cardiovascular events.
4.4.5 Treatment
Beyond secondary prevention of atherosclerosis, the treatment of
renal artery disease should be aimed at control of blood pressure
and preservation of renal function.
4.4.5.1 Medical treatment
ACE inhibitors and calcium channel blockers are effective in the
treatment of hypertension in the presence of RAS and may lead
to slowing of the progression of renal disease.181 Most patients
with haemodynamically significant RAS tolerate RAAS blockade
without difficulty. However, ACE inhibitors can reduce glomerular
capillary hydrostatic pressure enough to cause a transient decrease
in GFR and raise serum creatinine, warranting caution and close
follow-up. A significant (≥30%) fall in GFR (or a .0.5 mg/dL
rise in serum creatinine) may be an indication to consider renal
revascularization. ACE inhibitors are contraindicated in the case
of bilateral RAS and when this lesion affects a single functional
kidney.
There is evidence that thiazides, hydralazine, angiotensin II
receptor blockers, and b-blockers are also effective in achieving
target blood pressures in individuals with RAS.182 –184
All patients with atherosclerotic RAS should be treated accord-
ing to the European Guidelines on Cardiovascular Disease
Prevention.24
4.4.5.2 Revascularization
The decision regarding the potential revascularization strategy
should be based on the patient’s individual characteristics, such
as life expectancy, co-morbidities, quality of blood pressure
control, and renal function.
Evidence supporting the benefit of aggressive diagnosis and
timing of renal revascularization remains unclear. Among patients
receiving medical therapy alone, there is the risk for deterioration
of kidney function with worsening morbidity and mortality. Renal
artery revascularization can provide immediate improvement in
kidney function and blood pressure; however, as with all invasive
interventions, it may result in mortality or substantial morbidity
in a small percentage of patients. This is particularly the case for
renovascular lesions that pose no immediate hazard or risk of
Recommendations for diagnostic strategies for RAS
Recommendations Classa Levelb Ref c
DUS is recommended as 
the first-line imaging test to 
establish the diagnosis of RAS.
I B 171, 172
CTA (in patients with creatinine 
clearance >60 mL/min) is 
recommended to establish the 
diagnosis of RAS.
I B 151, 174
MRA (in patients with creatinine 
clearance >30 mL/min) is 
recommended to establish the 
diagnosis of RAS.
I B 174
When the clinical index 
of suspicion is high and 
the results of non-invasive 
tests are inconclusive, 
DSA is recommended as a 
diagnostic test (prepared for 
intervention) to establish the 
diagnosis of RAS.
I C -
Captopril renal scintigraphy, 
selective renal vein renin 
measurements, plasma renin 
activity, and the captopril 
test are not recommended 
as useful screening tests to 
establish the diagnosis of RAS.




CTA ¼ computed tomography angiography; DSA ¼ digital subtraction
angiography; DUS ¼ duplex ultrasonography; MRA ¼ magnetic resonance
angiography; RAS ¼ renal artery stenosis.
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progression. There is general consensus that renal revasculariza-
tion should be performed in patients with anatomically and func-
tionally significant RAS who present with particular clinical
scenarios such as sudden onset or ‘flash’ pulmonary oedema or
congestive heart failure with preserved left ventricular function
and acute oligo-/anuric renal failure with kidney ischaemia.
4.4.5.2.1 Impact of revascularization on blood pressure control
Twenty-one uncontrolled series of stenting/angioplasty published
before 2007 in 3368 patients gave no unifying pattern regarding
mortality rates. Cure, improvement, or worsening of arterial
hypertension was documented to range from 4% to 18%, from
35% to 79%, and from 0% to 13%, respectively. Two studies
reported a statistically significant reduction in the New York
Heart Association functional class after stent placement in patients
with either bilateral disease or stenosis to a solitary functioning
kidney (global ischaemia). For these patients with congestive
heart failure and repeated admissions for pulmonary oedema not
associated with CAD, improved volume management, restored
sensitivity to diuretics, and lowered rehospitalization rates
suggest that some individualized patient categories benefit substan-
tially from renal revascularization.185– 188
Three RCTs compared endovascular therapy with medical treat-
ment with ≥6 months of follow-up.166,183,189 Notably, these trials
were small and had no adequate power for clinical outcomes.
Stents were rarely used and medical therapies varied both
between and within studies. In a randomized study including 49
patients, the investigators concluded that endovascular therapy in
unilateral atherosclerotic RAS enables reduction of the number of
antihypertensive drugs,189 but that previous uncontrolled studies
overestimated the potential for lowering blood pressure. In the
Dutch Renal Artery Stenosis Intervention Cooperative (DRASTIC)
study involving 106 patients,166 there were no significant differences
between the angioplasty and drug therapy groups in terms of systolic
and diastolic blood pressures or renal function, whereas daily drug
doses were reduced in the angioplasty group. However, a significant
improvement in systolic and diastolic blood pressures was reported
after angioplasty in a meta-analysis of these three studies.190 Two
recent randomized trials comparing stent angioplasty combined
with medical therapy with medical therapy alone [Angioplasty and
Stenting for Renal Artery Lesions trial (ASTRAL) and the Stent Pla-
cement in Patients With Atherosclerotic Renal Artery Stenosis and
Impaired Renal Function (STAR)] failed to demonstrate any signifi-
cant difference in blood pressure.191,192 However, in the ASTRAL
trial, the daily drug dosage was reduced.191
4.4.5.2.2 Impact of revascularization on renal function
The ASTRAL trial is so far the largest RCT to determine whether
percutaneous revascularization combined with medical therapy
compared with medical therapy alone improves renal function.191
Eight-hundred and six patients with atherosclerotic RAS in whom
the need for revascularization was uncertain were enrolled. Fifty-
nine per cent of patients were reported to have RAS .70%, and
60% had a serum creatinine of ≥150 mmol/L. At a mean follow-up
of 33.6 months (range 1–4 years), differences in renal function and
kidney and cardiovascular events were all similarly unimpressive,
even in the highest risk groups, which included patients with global
ischaemia or impaired or rapidly decreasing kidney function. The
primary study endpoint—the decline in renal function over time—
calculated as the mean slope of the reciprocal of the serum creati-
nine concentration over time, was slightly slower in the revascular-
ization group, but the difference was not statistically significant.
The STAR multicentre trial enrolled 140 patients to detect a
≥20% decrease in creatinine clearance.192 At 2 years, the primary
endpoint was reached in 16% of patients in the stented group and
in 22% of patients in the medical treatment group. The difference
was not statistically significant and was inconclusive, given the wide
confidence intervals around the estimate of effect. It was noteworthy
that .50% of the patients randomized to stenting had a ,70%
diameter stenosis and 28% of patients did not receive a stent
(19%) because of no RAS .50%. This largely underpowered trial
showed that deterioration of renal function may progress despite
successful revascularization, underscoring the complex cause of
ischaemic nephropathy, with an important parenchymal component
affected by risk factors for atherosclerosis. It also showed that if
technical skills are insufficient, a considerable number of
stent-related complications can occur (two procedure-related
deaths, one death secondary to an infected haematoma, and one
case of deterioration of renal function resulting in dialysis).
4.4.5.2.3 Impact of revascularization on survival
In the ASTRAL and STAR trials no difference was seen in the sec-
ondary endpoints—cardiovascular morbidity and death. A recent
analysis of two consecutive registries comparing conservative
treatment with revascularization showed a 45% reduction in mor-
tality for the revascularization cohort.193 To date, no major differ-
ences in survival are evident between patients undergoing either
surgical or endovascular procedures, although only a few studies
addressed this issue directly.
Several factors may argue against renal revascularization or predict
poorer outcomes, including the presence of proteinuria .1 g/24 h,
renal atrophy, severe renal parenchymal disease, and severe diffuse
intrarenal arteriolar disease. Moreover, adverse consequences of
renal atheroembolization at the time of surgical revascularization
have been documented.194 Similarly, atheroembolization may be pro-
voked by percutaneous revascularization.192,195,196
The potential physiological benefits of renal stent placement
include reperfusion of the ischaemic kidney(s), resulting in a
reduction in the stimulus to renin production, which decreases
angiotensin and aldosterone production, thereby decreasing per-
ipheral arterial vasoconstriction and preventing hypervolaemia.
Improvement in renal perfusion enhances glomerular filtration
and therefore promotes natriuresis. Moreover, reduction of
humoral activation may result in reduction of left ventricular
mass and improvement of diastolic dysfunction.197 – 199
The ASTRAL study did not provide information on how to treat
patients with a clinical need for revascularization. This question is
being addressed by two ongoing RCTs. The Cardiovascular Out-
comes in Renal Atherosclerotic Lesions (CORAL) trial tests the
hypothesis that stenting atherosclerotic RAS .60% (systolic
pressure gradient .20 mmHg) in patients with systolic hyperten-
sion reduces the incidence of cardiovascular and renal events.
The Randomized, Multicentre, Prospective Study Comparing Best
Medical Treatment Versus Best Medical Treatment Plus Renal
Artery Stenting in Patients With Haemodynamically Relevant
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Atherosclerotic Renal Artery Stenosis (RADAR) investigates the
impact of renal stenting on the change in renal function in 300
patients.200
4.4.5.2.4 Technical outcomes of endovascular revascularization
Balloon angioplasty with bailout stent placement if necessary is rec-
ommended for fibromuscular dysplasia lesions.201– 204 In
atherosclerotic RAS, stent placement has consistently proven
superior to balloon angioplasty in the treatment of renal artery
atherosclerotic lesions.205 Restenosis rates range from 3.5% to
20%206,207; drug-eluting stents have not yet been shown to
achieve a significantly better outcome.208,209 The appropriate treat-
ment modality of in-stent RAS has not yet been defined. Balloon
angioplasty, bare-metal stent, covered stent, and drug-eluting stent
placement are still under investigation.210– 213 The role of distal pro-
tection devices is still a matter of debate. Following several promising
single-centre reports, results from a small, randomized trial196
showed no significantly improved renal function outcome for
distal filter protection during stent revascularization except when
an adjunctive glycoprotein IIb/IIIa receptor antagonist was used.
4.4.5.2.5 Role of surgical revascularization
Renal artery surgery offers major benefits for patients undergoing
surgical repair of the aorta, and for patients with complex disease
of the renal arteries, e.g. aneurysms or failed endovascular pro-
cedures. Thirty-day mortality rates range from 3.7% to 9.4%. After
a follow-up of up to 5 years, the need for reoperation has been
reported in 5–15% and survival in 65–81% of patients.214–218
Major arguments against surgical revascularization include higher
mortality linked to surgery in patients with co-morbidities and
similar benefits of endovascular repair.
The list of pivotal published and ongoing trials in patients with
RAS is provided in Appendix 4.
4.5 Lower extremity artery disease
4.5.1 Clinical presentation
LEAD has several different presentations, categorized according to
the Fontaine or Rutherford classifications (Table 5). Importantly,
even with a similar extent and level of disease progression, symp-
toms and their severity may vary from one patient to another.
4.5.1.1 Symptoms
Many patients are asymptomatic. In this situation, LEAD is diagnosed
by clinical examination (absent pulses) or by the ABI. Importantly,
asymptomatic patients are also at high risk for cardiovascular events.2
The most typical presentation of LEAD is intermittent claudication,
characterized by pain in the calves, increasing with walking; the pain
typically disappears quickly at rest (Fontaine stage II; Rutherford
grade I). In the case of a more proximal level of arterial obstruction
(i.e. the aortoiliac segment), patients may complain of pain extension
into the thighs and buttocks. Isolated buttock claudication is rare and
due to bilateral hypogastric severe disease. The pain should be distin-
guished from that related to venous disease (usually at rest, increasing
in the evening, often disappearing with some muscle activity), hip or
knee arthritis (pain on walking but not disappearing at rest), and per-
ipheral neuropathy (characterized more by instability while walking,
pain not relieved by resting). Typical intermittent claudication can
also be caused by lumbar spinal stenosis. The Edinburgh Claudication
Questionnaire224 is a standardized method to screen and diagnose
intermittent claudication, with a 80–90% sensitivity and .95% speci-
ficity (available online at http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC2560464/?page=1). More recently, several studies highlighted
that a substantial proportion of patients with symptomatic LEAD
present with atypical symptoms.225
Recommendations: treatment strategies for RAS
Recommendations Classa Levelb Ref c
Medical therapy
ACE inhibitors, angiotensin II 
receptor blockers, and calcium 
channel blockers are effective 
medications for treatment of 






ACE inhibitors and angiotensin 
II receptor blockers are 
contraindicated in bilateral 
severe RAS and in the case of 






Angioplasty, preferably with 
stenting, may be considered 
in the case of >60% 





In the case of indication 
for angioplasty, stenting 




Endovascular treatment of 
RAS may be considered in 





Treatment of RAS, by balloon 
angioplasty with or without 
stenting, may be considered 
for patients with RAS and 
unexplained recurrent 
congestive heart failure or 
sudden pulmonary oedema 




Surgical revascularization may 
be considered for patients 
undergoing surgical repair of 
the aorta, patients with complex 
anatomy of the renal arteries, 






ACE ¼ angiotensin-converting enzyme; RAS ¼ renal artery stenosis.
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In more severe cases pain is present at rest, in the supine position
(Fontaine stage III; Rutherford grade II). Rest pain is localized more
often in the foot and should be distinguished from muscle cramping
or arthritis. Patients often complain of permanent coldness in the
feet. Ulcers and gangrene (Fontaine stage IV; Rutherford grade III)
indicate severe ischaemia and begin mostly at the level of toes and
the distal part of the limb. Arterial ulcers are, in most cases, extre-
mely painful; they are frequently secondary to local trauma, even
minor, and should be distinguished from venous ulcers. When pain
is absent, peripheral neuropathy should be considered. Ulcers are
often complicated by local infection and inflammation.
Critical limb ischaemia is the most severe clinical manifestation
of LEAD, defined as the presence of ischaemic rest pain, and
ischaemic lesions or gangrene objectively attributable to arterial
occlusive disease.
4.5.1.2 Clinical examination
Clinical examination can be quite informative both for screening
and for diagnosis. Patients should be relaxed and acclimatized to
the room temperature. Inspection may show pallor in more
severe cases, sometimes at leg elevation. Pulse palpation is very
informative for screening purposes and should be done systemati-
cally. Pulse abolition is a specific rather than a sensitive clinical sign.
Auscultation of bruits over the femoral artery at the groin and
more distally is also suggestive, but poorly sensitive. The value of
the clinical findings in patients with LEAD can be strongly improved
by measuring the ABI. The blue toe syndrome is characterized by a
sudden cyanotic discolouration of one or more toes; it is usually
due to embolic atherosclerotic debris from the proximal arteries.
4.5.2 Diagnostic tests
4.5.2.1 Ankle–brachial index
The primary non-invasive test for the diagnosis of LEAD is the ABI.
In healthy persons, the ABI is .1.0. Usually an ABI ,0.90 is used
to define LEAD. The actual sensitivity and specificity have been
estimated, respectively, at 79% and 96%.226 For diagnosis in
primary care, an ABI ,0.8 or the mean of three ABIs ,0.90
had a positive predictive value of ≥95%; an ABI .1.10 or the
mean of three ABIs .1.00 had a negative predictive value of
≥99%.227 The level of ABI also correlates with LEAD severity,
with high risk of amputation when the ABI is ,0.50. An ABI
change .0.15 is generally required to consider worsening of
limb perfusion over time, or improving after revascularization.228
For its measurement (Figure 2), a 10–12 cm sphygmomanometer
cuff placed just above the ankle and a (handheld) Doppler instru-
ment (5–10 MHz) to measure the pressure of the posterior and
anterior tibial arteries of each foot are required. Usually the
highest ankle systolic pressure is divided by the highest brachial sys-
tolic pressure, resulting in an ABI per leg. Recently some papers
reported higher sensitivity to detect LEAD if the ABI numerator is
the lowest pressure in the arteries of both ankles.229




Stage Symptoms Grade Category Symptoms




























LEAD ¼ lower extremity artery disease.




ibliotheque Fac de M






Measuring ABI after exercise enables the detection of additional
subjects with LEAD, who have normal or borderline ABI at rest.
The patient is asked to walk (commonly on a treadmill at 3.2 km/
h at a 10–20% slope) until claudication pain occurs and impedes
walking. An ABI drop after exercise seems especially useful when
resting ABI is normal but there is clinical suspicion of LEAD.230
Some patients have an ABI .1.40, related to stiff (calcified)
arteries, a condition often observed in the case of diabetes,
ESRD, and in the very elderly. Importantly, a substantial proportion
of patients with an elevated ABI actually do have occlusive artery
disease.231 Alternative tests such as measurement of toe systolic
pressures and Doppler waveform analysis are useful to unmask
LEAD.231 A toe–brachial index ,0.70 is usually considered diag-
nostic of LEAD.
4.5.2.2 Treadmill test
The treadmill test is an excellent tool for obtaining objective
functional information, mainly on symptom onset distance and
maximum walking distance. It is useful in patients with border-
line ABI at rest with symptoms suggestive of LEAD. It can
also help to differentiate vascular claudication (with leg pressure
drop after exercise) from neurogenic claudication (leg pressure
remains stable or increases). The standardized treadmill test is
also proposed to assess treatment efficacy (exercise rehabilita-
tion, drug therapies, and/or revascularization) during follow-up.
Usually the test is performed on a treadmill walking at
3.2 km/h with a 10% slope. However, there are several technical
variations,232 such as introducing a steady increase in elevation
of the treadmill every 3 min while keeping the speed constant.
The test should be supervised to observe all symptoms occur-
ring during the test. It should be avoided in the case of severe
CAD, decompensated heart failure, or major gait disturbances.
It is usually associated with ABI measurement before and after
exercise. A pressure drop .20% immediately after exercise
confirms the arterial origin of symptoms.233 For patients
unable to perform treadmill exercise, alternative tests such as
repeated pedal flexions can be used, with excellent correlation
with the treadmill test.
4.5.2.3 Ultrasound methods
DUS provides extensive information on both arterial anatomy and
blood flow. Compared with DSA, several concordant meta-analyses
estimated DUS sensitivity to detect .50% diameter angiographic
stenosis at 85–90%, with a specificity .95%.236 –238 No significant
differences were found between the above- and below-knee
lesions.236,238 DUS can also visualize run-off vessels, especially
when using the colour mode. DUS depends greatly on the exami-
ner’s experience, and adequate qualification and training are manda-
tory. Combined with the ABI, DUS provides all the information
necessary for management decisions in the majority of patients
with LEAD, confirms the diagnosis, and provides information on
lesion location and severity. The lesions are located by two-
dimensional (2D) ultrasonography and colour-Doppler mapping,
while the degree of stenosis is estimated mostly by Doppler wave-
form analysis and peak systolic velocities and ratios. The interobser-
ver reproducibility of the DUS to detect .50% stenosis in lower
extremity arteries is good, except for pedal arteries.239,240
DUS is also highly useful for the follow-up after angioplasty or to
monitor bypass grafts.241,242 Excellent tolerance and lack of radiation
exposure make DUS the method of choice for routine follow-up.
Pitfalls of DUS are related mainly to difficulties in assessing the
lumen in highly calcified arteries. Insonation in the area of open
ulcers or excessive scarring may not be possible. Also in some
cases (e.g. obesity, gas interpositions), the iliac arteries are more
difficult to visualize and alternative methods should be considered
when the imaging is suboptimal. The major disadvantage of DUS
compared with other imaging techniques (DSA, CTA, or MRA)
is that it does not provide full arterial imaging as a clear
roadmap, as do the other techniques. However, in contrast to
other imaging technique (DSA, CTA, and MRA), DUS provides
important information on haemodynamics. Complete DUS scan-
ning of the entire arterial network can be time-consuming.
Although aggregate images or schemas can be provided, another
imaging technique is usually required, especially when bypass is
Recommendations for ABI measurement
Recommendations Classa Levelb Ref c
Measurement of the ABI is 
indicated as a first-line non-
invasive test for screening and 
diagnosis of LEAD.
I B 226
In the case of incompressible 
ankle arteries or ABI >1.40, 
alternative methods such 
as the toe-brachial index, 
Doppler waveform analysis or 






ABI ¼ ankle–brachial index; LEAD ¼ lower extremity artery disease.
Recommendations for treadmill testing in patients with
LEAD
Recommendations Classa Levelb Ref c
The treadmill test should be 
considered for the objective 
assessment of treatment 
to improve symptoms in 
claudicants.
IIa A 234, 235
In the case of typical or 
atypical symptoms suggestive 
of LEAD, the treadmill test 
should be considered for 
diagnostic confirmation and/or 
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considered.243 However, even in this situation, DUS can be an
important aid in determining the most appropriate site of anasto-
mosis by identification of the least calcified portion of the vessel.244
Intravascular ultrasound has been proposed for plaque charac-
terization and after angioplasty, but its routine role in the clinical
setting requires further investigation.
4.5.2.4 Computed tomography angiography
CTA using MDCT technology allows imaging with high resolution.
Compared with DSA, the sensitivity and specificity for occlusions
reported using the single-detector techniques already reached a
high degree of accuracy. In a recent meta-analysis, the reported
sensitivity and specificity of CTA to detect aortoiliac stenoses
.50% were 96% and 98%, respectively.245 The same study
showed similar sensitivity (97%) and specificity (94%) for the
femoropopliteal region, comparable with those reported for the
below-knee arteries (sensitivity 95%, specificity 91%).245
The great advantage of CTA remains the visualization of calcifi-
cations, clips, stents, and bypasses. However, some artefacts may
be present due to the ‘blooming effect’.
4.5.2.5 Magnetic resonance angiography
MRA can non-invasively visualize the lower limb arteries even in
the most distal parts. The resolution of MRA using
gadolinium-enhanced contrast techniques reaches that of DSA. In
comparison with DSA, MRA has an excellent sensitivity (93–
100%) and specificity (93–100%).237,246 –250 Owing to different
techniques (2D and 3D, with or without gadolinium), the results
are not as uniform as for CTA, and studies comparing MRA with
CTA are not available. In direct comparison, MRA has the greatest
ability to replace diagnostic DSA in symptomatic patients to assist
decision making, especially in the case of major allergies. There are
also limitations for the use of MRA in the presence of pacemakers
or metal implants (including stents), or in patients with claustro-
phobia. Gadolinium contrast agents cannot be used in the case
of severe renal failure (GFR ,30 mL/min per 1.73 m2). Of note,
MRA cannot visualize arterial calcifications, which may be a limit-
ation for the selection of the anastomotic site for a surgical bypass.
4.5.2.6 Digital subtraction angiography
For the aorta and peripheral arteries, retrograde transfemoral cathe-
terization is usually used. Cross-over techniques allow the direct
antegrade flow imaging from one side to the other. If the femoral
access is not possible, transradial or transbrachial approaches and
direct antegrade catheterization are needed. Considered as the
gold standard for decades, DSA is now reserved for patients under-
going interventions, especially concomitant to endovascular pro-
cedures. Indeed, the non-invasive techniques provide satisfying
imaging in almost all cases, with less radiation, and avoiding compli-
cations inherent to the arterial puncture, reported in ,1% of cases.
4.5.2.7 Other tests
Several other non-invasive tests can be used routinely, either to
localize the lesions or to evaluate their effect on limb perfusion:
segmental pressure measurements and pulse volume record-
ings,251 (laser) Doppler flowmetry, transcutaneous oxygen
pressure assessment (TCPO2), and venous occlusion plethysmo-
graphy before and during reactive hyperaemia.252
4.5.3 Therapeutic strategies
All patients with LEAD are at increased risk of further CVD events,
and general secondary prevention is mandatory to improve prog-
nosis. Patients with asymptomatic LEAD have no indication for
prophylactic revascularization. The following paragraphs focus on
the treatment of symptomatic LEAD.
4.5.3.1 Conservative treatment
The aim of conservative treatment in patients with intermittent
claudication is to improve symptoms, i.e. increase walking distance
and comfort. To increase walking distance, two strategies are cur-
rently used: exercise therapy and pharmacotherapy.
4.5.3.1.1 Exercise therapy
In patients with LEAD, training therapy is effective in improving
symptoms and increasing exercise capacity. In a meta-analysis253
including data from 1200 participants with stable leg pain, com-
pared with usual care or placebo, exercise significantly improved
maximal walking time, with an overall improvement in walking
ability of 50–200%. Walking distances were also significantly
improved. Improvements were seen for up to 2 years. Best evi-
dence comes from studies with a short period of regular and inten-
sive training under supervised conditions.254 In a meta-analysis of
eight trials collecting data from only 319 patients, supervised exer-
cise therapy showed statistically significant and clinically relevant
differences in improvement of maximal treadmill walking distance
compared with non-supervised exercise therapy regimens
(+150 m on average).255 In general, the training programme lasts
for 3 months, with three sessions per week. The training intensity
on the treadmill increases over time, with a session duration of
Recommendations for diagnostic tests in patients with
LEAD
Recommendations Classa Levelb Ref c
Non-invasive assessment 
methods such as segmental 
systolic pressure measurement 
and pulse volume recording, 
plethysmography, Doppler 
flowmetry, and DUS are 
indicated as first-line methods 
to confirm and localize LEAD 
lesions.
I B 251, 252
DUS and/or CTA and/or 
MRA are indicated to localize 





The data from anatomical 
imaging tests should always be 
analysed in conjunction with 






CTA ¼ computed tomography angiography; DUS ¼ duplex ultrasonography;
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30–60 min.256 Of note, in a small randomized trial257 comparing
supervised exercise therapy with usual care, while no significant
changes in peak cardiovascular measurements were noted after
12 weeks of exercise, patients under supervised exercise therapy
were more efficient in meeting the circulation and ventilation
demands of exercise.
Individuals with LEAD should undertake exercise as a form of
treatment. Any type of regular exercise should be continued
after completion of the intensive training programme. Daily
walking, or repeated series of heel raising or knee bending, are rea-
listic possibilities.258 Other training programmes have been
suggested, but their effectiveness is less well documented. In a
pilot trial, dynamic arm exercise training was followed by similar
improvement (pain-free and maximal walking distance) to that
seen with treadmill walking exercise training.259
There are obvious limitations to training therapy. Muscular,
articular, or neurological diseases may be limiting factors.
General cardiac and/or pulmonary diseases can decrease capacity
to achieve a level of training that is sufficient to obtain positive
results. In conjunction with practical aspects, such as difficulties
in attending the sessions or neglecting continuous training, the
actual results in the clinical setting have often been poorer than
in trials. Patients with Fontaine class IV should not be submitted
to regular exercise training.
4.5.3.1.2 Pharmacotherapy
Several pharmacological approaches were claimed to increase
walking distance in patients with intermittent claudication.
However, objective documentation of such an effect is often
lacking or limited. In terms of walking distance improvement, the
benefits, if any, are generally mild to moderate, with wide confi-
dence of intervals. Also, mechanisms of action are diversified and
often unclear. The drugs with best proof of efficacy are discussed
briefly below. Among them, the best-documented drugs are cilos-
tazol and naftidrofuryl.
4.5.3.1.2.1 Cilostazol
Cilostazol is a phosphodiesterase-3 inhibitor. In a pooled analysis
of nine trials (1258 patients) comparing cilostazol with
placebo,260 this drug was associated with an absolute improvement
of +42.1 m vs. placebo (P ,0.001) over a mean follow-up of 20
weeks. In another meta-analysis,261 maximal walking distance
increased on average by 36 m with cilostazol 50 mg/day, and
almost twice (70 m) with the 100 mg dose. Improvement in
quality of life is also reported in claudicants.262 Owing to its
pharmacological properties, it should be avoided in the case of
heart failure. The most frequent side effects are headache, diar-
rhoea, dizziness, and palpitations.
4.5.3.1.2.2 Naftidrofuryl
Naftidrofuryl has been available in Europe for many years. It is a
5-hydroxytryptamine type 2 antagonist that reduces erythrocyte
and platelet aggregation. The efficacy of naftidrofuryl was examined
in a meta-analysis of five studies including 888 patients: pain-free
walking distance was significantly increased by 26% vs.
placebo.263 This positive effect on intermittent claudication was
confirmed by a recent Cochrane analysis.264 Quality of life was
also improved with naftidrofuryl treatment.265 Mild gastrointestinal
disorders are the most frequently observed side effect.
4.5.3.1.2.3 Pentoxifylline
This phosphodiesterase inhibitor was among the first drugs to
show improvement in red and white cell deformability, and, as a
consequence, decrease blood viscosity. In a recent meta-analysis261
of six studies including 788 patients, a significant increase in
maximal walking distance was found with pentoxifylline (+59 m).
4.5.3.1.2.4 Carnitine and propionyl-L-carnitine
These drugs are likely to have an effect on ischaemic muscle
metabolism. In two multicentre trials,266,267 propionyl-L-carnitine
improved walking distance and quality of life better than placebo.
Additional trials are expected to evaluate their efficacy in large
groups of patients.
4.5.3.1.2.4 Buflomedil
Buflomedil may cause inhibition of platelet aggregation and
improve red blood cell deformability. It also has a-1 and a-2 adre-
nolytic effects. In a recent placebo-controlled study in 2078
patients,268 significant symptomatic improvement was shown.
However, in a recent meta-analysis,269 these results were quoted
as ‘moderately’ positive, with some degree of publication bias.
The therapeutic dose range is narrow, with a risk of seizures.270
Buflomedil has been recently withdrawn from the market in
some European countries for potential major side effects and
uncertain benefits.
4.5.3.1.2.5 Antihypertensive drugs
In a recent review, antihypertensive drugs did not differ in respect
of their effect on intermittent claudication.271According to a
recent meta-analysis of four studies, the benefits of ACE inhibitors
on walking distance are uncertain, and the main expectation of pre-
scribing this drug class is in the general prognostic improvement of
these patients (see Section 3.4.4).272 Notably, b-blockers do not
exert a negative effect on claudication.273,274
4.5.3.1.2.6 Lipid-lowering agents
Beyond the evidence that statins improve the cardiovascular prog-
nosis of patients with LEAD, several studies reported preliminary
positive effects of statins on intermittent claudication.261 The
increase in maximal walking distance reported varied, on average,
from 50 to 100 m. In one meta-analysis, the pooled effect estimate
was in favour of lipid-lowering agents, with a relevant increase in
maximal walking distance of 163 m.261
4.5.3.1.2.7 Antiplatelet agents
The use of antiplatelet drugs is indicated in patients with LEAD to
improve event-free survival (see Section 3.4.3). In contrast, data on
the potential benefits of antiplatelet drugs to improve clinical
symptoms are scarce. In a recent meta-analysis,261 data from
studies assessing five drugs (ticlopidine, cloricromene, mesoglycan,
indobufen, and defibrotide) were pooled, with a significant
increase in maximal walking distance of 59 m. Available data are
too disparate to formulate any conclusions.
4.5.3.1.2.8 Other therapies
Other pharmacological agents assessed are inositol, proteoglycans,
and prostaglandins. Although positive, the results require further
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confirmation. A recent meta-analysis showed no significant
improvement in walking distance with gingko biloba.275
Intermittent pneumatic compression may be a relevant treat-
ment for symptomatic LEAD. In a review,276 concordant data are
reported in several studies showing increased flow (13–240%) in
the popliteal or infragenicular arteries. Rest pain and walking
distance were also improved. In a recent small, randomized trial
comparing a portable intermittent pneumatic compression device
with best medical therapy, maximal walking distance improved
by 50% (90 m).277
4.5.3.2 Endovascular treatment of lower extremity artery disease
Endovascular revascularization for the treatment of patients with
LEAD has developed rapidly during the past decade, and a great
number of patients can now be offered the less invasive treatment
option. An increasing number of centres favour an endovascular-
first approach due to reduced morbidity and mortality—compared
with vascular surgery—while preserving the surgical option in case
of failure.
The optimal treatment strategy concerning endovascular vs. sur-
gical intervention is often debated due to the paucity of randomized
studies; furthermore, most of these studies are underpowered.
Moreover, owing to the rapid development, a thorough evaluation
of new endovascular treatment options within adequately designed
clinical studies is difficult. Another problem is the lack of uniform
endpoint definitions, making a direct comparison among studies dif-
ficult.278 It is important to report results including clinical, morpho-
logical, and haemodynamic outcomes.
The selection of the most appropriate revascularization strategy
has to be determined on a case-by-case basis in a specialized vas-
cular centre in close cooperation with an endovascular specialist
and a vascular surgeon. The main issues to be considered are
the anatomical suitability (Table 6), co-morbidities, local availability
and expertise, and the patient’s preference.
While revascularization is obligatory in patients with CLI, the evi-
dence of any long-term benefit of endovascular treatment over
supervised exercise and best medical treatment is inconclusive,
especially in patients with mild to moderate claudication.279
However, advances in the endovascular treatment of LEAD have
prompted many physicians to consider more liberal indications for
percutaneous intervention. Endovascular revascularization is also
indicated in patients with lifestyle-limiting claudication when clinical
features suggest a reasonable likelihood of symptomatic improve-
ment and there has been an inadequate response to conservative
therapy. In aortoiliac lesions, endovascular revascularization can be
considered without initial extensive conservative treatment.
The major drawback of endovascular interventions—compared
with surgery—is the lower long-term patency. The primary
patency after angioplasty is greatest for lesions in the common
iliac artery and decreases distally, and with increasing length, mul-
tiple and diffuse lesions, poor-quality run-off, diabetes, and renal
failure. Currently there is no established method—besides stent
implantation—to improve at least the mid-term patency of angio-
plasty. The use of drug-eluting balloons seems promising; however,
the current limited data do not justify a general recommendation.
In general, endovascular interventions are not indicated as pro-
phylactic therapy in an asymptomatic patient. Patients undergoing
Table 6 Lesion classification according to the
TransAtlantic Inter-Society Consensus for the




- Unilateral or bilateral stenosis of CIA
- Unilateral or bilateral single short (≤3 cm) stenosis 
 of EIA
Type B
- Short (≤3 cm) stenosis of infrarenal aorta
- Unilateral CIA occlusion
- Single or multiple stenosis totaling 3-10 cm 
 involving the EIA not extending into the CFA
- Unilateral EIA occlusion not involving the origins of 
 internal iliac or CFA
Type C
- Bilateral CIA occlusions
- Bilateral EIA stenoses 3-10 cm long not extending 
 into the CFA
- Unilateral EIA stenosis extending into the CFA
- Unilateral EIA occlusion that involves the origins of 
 internal iliac and/or CFA
- Heavily calcified unilateral EIA occlusion with or 
 without involvement of origins of internal iliac and/
 or CFA
Type D
- Infra-renal aorto-iliac occlusion
- Diffuse disease involving the aorta and both iliac 
 arteries requiring treatment
- Diffuse multiple stenosis involving the unilateral 
 CIA, EIA and CFA
- Unilateral occlusions of both CIA and EIA
- Bilateral occlusions of EIA
- Iliac stenosis in patients with AAA requiring 
 treatment and not amenable to endograft 
 placement or other laesions requiring open aortic 




- Single stenosis ≤10 cm in length
- Single occlusion ≤5 cm in length
Type B
- Multiple lesions (stenoses or occlusions), 
 each ≤5 cm
- Single stenosis or occlusion ≤15 cm not involving 
 the infra geniculate popliteal artery
- Single or multiple lesions in the absence of 
 continuous tibial vessels to improve inflow for a 
 distal bypass
- Heavily calcified occlusion ≤5 cm in length
- Single popliteal stenosis
Type C
- Multiple stenoses or occlusions totaling >15 cm 
 with or without heavy calcifications
- Recurrent stenoses or occlusions that need 
 treatment after two endovascular interventions
Type D
- Chronic total occlusion of CFA or SFA (>20 cm, 
 involving the popliteal artery)
- Chronic total occlusion of popliteal artery and 
 proximal trifurcation vessels
AAA ¼ abdominal aortic aneurysm; CFA ¼ common femoral artery;
CIA ¼ common iliac artery; EIA ¼ external iliac artery; SFA ¼ superficial femoral
artery.
After Norgren et al.6 with permission.
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endovascular revascularization for claudication or CLI should be
entered into a clinical surveillance programme.
The primary goals of stent implantation are: (i) to improve an
insufficient primary result—residual stenosis, extensive recoil,
flow-limiting dissection; and (ii) to improve long-term patency.
The placement of stents should generally be avoided in bending
areas (hip and knee joints), although special stents have been
developed recently. Stent implantation should also be avoided in
a segment suitable as a landing zone for a potential bypass.
4.5.3.2.1 Aortoiliac segment
Obstructive atherosclerotic disease of the distal aorta and iliac
arteries is preferentially treated with endovascular techniques, and
an endovascular-first strategy can be recommended for all TransAt-
lantic Inter-Society Consensus (TASC) A–C lesions. Low morbidity
and mortality as well as a .90% technical success rate justify the
endovascular-first approach. In experienced centres, TASC D
lesions are also primarily treated percutaneously. The main limitation
in recommending the endovascular-first strategy for almost all aor-
toiliac lesions is the lack of published data from randomized trials.
The only randomized trial comparing primary stent implantation
with provisional stenting in the case of a persistent pressure gradi-
ent after angioplasty alone did not demonstrate any benefit of
primary stent implantation.280 Based on an older meta-analysis,
stenting can be recommended as the primary therapy for
common and external iliac stenosis and occlusions.281 The
patency rates with stenting of iliac arteries compare favourably
with those of surgical revascularization.282
The choice of balloon vs. self-expandable stents is determined
mainly by operator preference. The main advantages of balloon-
expandable stents are the higher radial stiffness and the more accu-
rate placement, which is especially important in bifurcation
lesions.283 In the external iliac artery, a primary stenting strategy
using self-expandable stents compared with provisional stenting is
preferred mainly due to a lower risk of dissection and elastic recoil.
In the case of doubt about the haemodynamic significance of
morphologically borderline iliac lesions, pressure gradients at rest
and with induced hyperaemia should be measured.284
4.5.3.2.2 Femoropopliteal segment
One of the main problems with endovascular therapy in this
segment is the high prevalence of diffuse disease. Furthermore,
different mechanical forces act on the superficial femoral artery.
This artery is deformed repetitively in multiple directions by leg
movements. A high technical success rate, due to technical devel-
opments and increasing operator experience, in combination with
low risk, make endovascular therapy the preferred choice also in
patients with long and complex femoropopliteal lesions.
The landscape of endovascular treatment of femoropopliteal
disease has changed decisively with the development of self-
expandable nitinol stents. The previous strategy was to use
stents as the treatment option only in the case of initial PTA
failure or late recurrence. However, according to an increasing
number of randomized studies, primary nitinol stenting can now
be recommended as the first-line treatment for intermediate
length superficial femoral artery lesions due to improvement of
at least mid-term patency.285,286 The restenosis rate after 1–2
years is 20–30% lower after primary stenting compared with
angioplasty.
The decision to stent the superficial femoral artery is based
mainly on the clinical indication for revascularization and on the
lesion length and complexity. In the case of CLI, stenting can be
applied more liberally for limb salvage and ulcer healing.
In the past, there was much concern about stent fractures.
Several risk factors have been identified for stent fractures:
number and length of implanted stents, overlapping stents,
amount of calcification, and deployment technique.287 The higher
fracture resistance of the latest generation of stents in combination
with the production of long nitinol stents (up to 20 cm in length)
broadens the possibilities of endovascular therapies in the case of
more difficult and complex lesions.
In-stent restenosis is the major drawback of stent implantation.
To date there is no proof of any impact of stent design on reste-
nosis rates. Isolated balloon angioplasty of restenosis lesions has a
very high failure rate. Other treatment modalities have been inves-
tigated, but there is no single randomized trial in patients with
in-stent restenosis demonstrating the superiority of one technique
over the other. Drug-eluting stents have been investigated in a few
studies in the superficial femoral artery, and until now no advan-
tage has been shown compared with bare-metal nitinol stents.288
Early studies with drug-eluting balloons in the femoropopliteal
arteries showed improved short-term patency rates compared
with plain balloon angioplasty.289
Covered stents (stent grafts) appear to be a viable option for the
treatment of complex superficial femoral artery lesions, with out-
comes comparable with prosthetic above-knee femoropopliteal
bypass surgery.290
Despite its widespread use, research data regarding subintimal
angioplasty are sparse. There are no data comparing patency rates
between intraluminal and subintimal angioplasty. However, in
many interventions an unintentional subintimal passage is unavoid-
able. Regarding atherectomy, different devices are used with
unclear long-term benefits. Currently there are niche indications
in severely calcified lesions and non-stent areas (e.g. the common
femoral and popliteal artery). However, there are some concerns
regarding the risk of distal embolization with these devices.
Recommendations for revascularization in patients
with aortoiliac lesions
Recommendations Classa Levelb
When revascularization is indicated, an 
endovascular-first strategy is recommended in 
all aortoiliac TASC A–C lesions.
I C
A primary endovascular approach may be 
considered in aortoiliac TASC D lesions in 
patients with severe comorbidities, if done by 
an experienced team.
IIb C
Primary stent implantation rather than 





TASC ¼ TransAtlantic Inter-Society Consensus.
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Most patients with CLI have multisegmental disease involving the
infrapopliteal arteries. Therefore, limb salvage is the primary indi-
cation for endovascular treatment of infrapopliteal lesions, while
angioplasty of these arteries is usually not indicated in patients
with intermittent claudication. There is increasing evidence to
support a recommendation for angioplasty in patients with CLI
where straight-line flow to the foot in at least one lower leg
artery can be re-established according to the pre-interventional
angiogram and in the case of important co-morbidities.292
Primary PTA remains the standard of care, as it provides an
acceptable clinical outcome at a low procedural cost.293 The
limb salvage rate is definitely higher than the angiographic
patency rate after initially successful intervention below the knee.
Therefore, long-term patency is not obligatory in CLI patients
with persistent clinical improvement. Stent implantation in infrapo-
pliteal vessels is generally reserved for cases with a suboptimal
outcome after PTA. The use of drug-eluting stents is associated
with a favourable restenosis rate294; the balloon-expandable
sirolimus-eluting stent is approved in Europe for this indication.
4.5.3.3 Surgery
Vascular surgery offers different revascularization techniques for
lower limb ischaemia. Bypass surgery presents the most common
surgical approach for diffuse occlusive disease and creates new con-
duits following anatomical or extra-anatomical routes. In some cir-
cumstances, local endarterectomy with or without patching can
restore blood perfusion. Different graft materials can be applied.
Autologous vein or artery grafts are the best options, but are not
always available or applicable. In such cases, prosthetic grafts are
considered. Homografts represent the third option for vascular sub-
stitution, especially in the case of infective complications.
Patients with extensive necrosis or infectious gangrene and those
who are non-ambulatory may best be served with primary amputa-
tion. Amputation remains the last surgical step to solve irreversible
limb ischaemia, allowing patient recovery with rehabilitation and
prosthesis. For a moribund patient, adequate analgesia and other
supportive measures may also be the best option. Other adjuvant
surgical options can be considered. Skin reconstruction is useful
to cover large areas of lost tissue. The use of lumbar sympathectomy
is controversial and is not supported by evidence.
4.5.3.3.1 Aortoiliac disease
Aorto-biiliac or -bifemoral bypass is usually recommended for
diffuse aortoiliac disease. In some situations, when an abdominal
approach is perilous, a modified retroperitoneal approach or a uni-
lateral bypass with a femoro-femoral cross-over may be considered.
Other extra-anatomical surgical alternatives are axillo(bi)femoral or
thoracic(bi)femoral bypasses. The surgical strategy depends on the
lesion location and technical possibilities. Compared with the aorto-
femoral bypass, extra-anatomical bypasses present poorer patency
rates and higher risk of complications. The 10-year primary
patency rates of aortobifemoral bypass range from 80% to 90%.295
4.5.3.3.2 Infrainguinal disease
When infrainguinal disease is the cause of claudication, the appro-
priateness of intervention is more debated than for aortoiliac
disease, depending on the level of symptoms, quality of femoral
profundis artery and its collaterals, and local haemodynamic
status. In contrast, in the case of CLI, any patent proximal vessel,
including the iliac, common, or superficial femoral arteries,
femoral profundis, and popliteal arteries, may serve as the inflow
vessel for distal arterial reconstruction. Autologous vein grafts (in
situ or reversed vein graft, or using the contralateral saphenous
vein) provide the best patency results.296 Prosthetic grafts may
be used if the autogenous vein is not available. Conflicting results
are reported on the usefulness of vein cuffs to improve graft
patency.297,298 In a recent meta-analysis299 involving data from
seven contemporary trials (1521 patients) comparing Dacron
with polytetrafluoroethylene femoropopliteal bypasses, the cumu-
lative primary patency rates were similar at 3 years (60.2% vs.
53.8%, respectively) and at 5 years (49.2% vs. 38.4%). Pooling the
three studies that included exclusively above-knee femoropopliteal
Recommendations for revascularization in patients
with femoropopliteal lesions
Recommendations Classa Levelb Ref c
When revascularization is 
indicated, an endovascular-first 
strategy is recommended in 
all femoropopliteal TASC A–C 
lesions.
I C -
Primary stent implantation 
should be considered in 





A primary endovascular 
approach may also be 
considered in TASC D 
lesions in patients with 
severe comorbidities and the 
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When revascularization in the infrapopliteal 
segment is indicated, the endovascular-first 
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IIa C
For infrapopliteal lesions, angioplasty is the 
preferred technique, and stent implantation 
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bypasses revealed lower risk for primary occlusion with Dacron
grafts (HR 0.71 vs. polytetrafluoroethylene, P ¼ 0.003), but long-
term results are awaited. The pooled weighted data for 1-, 3-,
and 5-year primary patency rates for femorodistal (tibial or
pedal) bypasses are, respectively, reported at 85, 80, and 70%
for venous bypass and 70, 35, and 25% with a prosthetic graft.6
In one trial with above-knee grafting, the 4-year primary and sec-
ondary patency rates were significantly better with the use of
the saphenous vein (73% and 90%, respectively) compared with
polytetrafluoroethylene (47% and 47%, both P ,0.05) and
Dacron (54% and 60%, both P ,0.01). Two trials comparing in
situ and reversed saphenous vein grafts to the above- and below-
knee popliteal artery revealed no differences in primary and sec-
ondary patency as well as survival with an intact limb. Three
trials comparing polytetrafluoroethylene with human umbilical
vein showed significantly higher secondary patency rates with the
latter.300 Comparison of polytetrafluoroethylene grafts with and
without a vein cuff found no difference in above-knee grafts.
However, primary patency for below-knee bypass was higher
with a polytetrafluoroethylene prosthesis with vein cuff bypass at
2 years.296,301
Only one randomized trial has compared angioplasty with infra-
inguinal bypass. In the Bypass versus Angioplasty in Severe Ischae-
mia of the Leg (BASIL) trial, 452 patients with severe limb
ischaemia due to infrainguinal disease were randomized to angio-
plasty or infrainguinal bypass. The primary endpoint was
amputation-free survival. Secondary endpoints included all-cause
mortality, morbidity, reintervention, quality of life, and hospital
costs.302 The 30-day mortality was similar in both groups (5%
for surgery and 3% for angioplasty). However, surgery was associ-
ated with a higher morbidity (57% vs. 41%), mainly due to myocar-
dial infarction and wound infection. Moreover, surgery was more
expensive during the first year, due to the longer hospital stay.
The 6-month amputation-free survival was similar in both strat-
egies. Angioplasty patients presented higher failure rates (20% vs.
3% at 1 year), resulting in higher reintervention rates (27% vs.
17%). These results suggest that surgical revascularization is
superior to angioplasty in patients with good quality veins for
bypass. Recently additional data with a longer follow-up period
(.3 years) have been published211,303: overall, there was no signifi-
cant difference in amputation-free or overall survival between the
two strategies. However, for patients who survived for at least 2
years after randomization, the surgery-first revascularization strat-
egy was associated with a significant increase in subsequent overall
survival and a trend towards improved amputation-free survival.
One small, randomized trial comparing stenting with
femoral-to-above-knee prosthetic bypass found no difference in
primary and secondary patency rates at 12 months.290 Further
trials are required comparing infrainguinal stenting with surgery.
Another infrainguinal surgical reconstruction is the profundoplasty,
the correction of a stenosis at the origin of the deep femoral artery.
It may be considered as an inflow procedure, instead of a distal
bypass, in the presence of an excellent proximal inflow, .50% ste-
nosis of the proximal third of the profunda femoris artery, and the
presence of excellent collateral flow to the tibial vessels.
Secondary amputation should be performed when revasculariza-
tion has failed and reintervention is no longer possible or when the
limb continues to deteriorate because of infection or necrosis
despite a patent graft. The goals of secondary amputation are:
ischaemic pain relief, complete removal of diseased, necrotic, or
infected tissue, and construction of a stump suitable for ambulation
with prosthesis.
4.5.3.3.3 Surveillance
Clinical surveillance including clinical assessment and ankle
pressure follow-up should be performed following any revascular-
ization procedure. Although there is no consensual protocol of
surveillance, regular monitoring of revascularized limbs can
permit a prompt prophylactic intervention (e.g. repair of an arterial
bypass at high risk of occlusion according to DUS criteria) and
improve long-term patency.305 However, in a multicentre random-
ized trial including 594 patients with vein grafts, a systematic duplex
surveillance programme was not found to be beneficial in terms of
graft patency and limb survival rates, and was less cost-effective
than clinical surveillance.306 DUS could be useful to select high-risk
prosthetic grafts, which may require long-term anticoagulation to
reduce the risk of graft thrombosis,307 but these data are based
on observational series and require confirmation in trials.
4.5.3.3.4 Antiplatelet and anticoagulant therapy after revascularization
Beyond potential benefits of antiplatelet agents to reduce fatal or
non-fatal CVD events in patients with LEAD, these drugs are
also specifically proposed after revascularization to improve
patency rates. In a meta-analysis of 16 studies, the effect of antipla-
telet therapy administered post-operatively was evaluated in
patients receiving infrainguinal bypasses.308 Antiplatelet treatment
with aspirin or a combination of aspirin and dipyridamole had an
overall positive effect on primary patency 12 months after the pro-
cedure (OR 0.59, 95% CI 0.45–0.79). Subgroup analysis indicated
that patients receiving a prosthetic graft were more likely to
benefit from administration of platelet inhibitors than patients
treated with venous grafts.308 The multicentre, prospective
Dutch Bypass Oral Anticoagulants or Aspirin (BOA) trial309 ran-
domized 2690 lower extremity bypass patients into two groups:
anticoagulation (with the international normalized ratio targeted
within the 3.0–4.5 interval) vs. antiplatelet therapy (aspirin
80 mg/day). Overall patency rates did not differ, but the results
of a subgroup analysis suggested that oral anticoagulation improved
vein graft patency compared with aspirin. Conversely, aspirin
Recommendation for surgical revascularization in
patients with LEAD
Recommendations Classa Levelb Ref c
When surgery is considered 
to revascularize infrailiac 
lesions, the autologous 
saphenous vein is the bypass 
graft of choice.
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improved prosthetic graft patency vs. anticoagulation. Notably, the
risk of major bleeding was two-fold higher in the anticoagulation
group. In another trial,310 665 patients undergoing femoropopliteal
bypass were randomized to aspirin (325 mg/day) plus warfarin
(goal international normalized ratio 1.4–2.8) vs. aspirin (325 mg/
day) alone. This trial failed to demonstrate any improvement in
terms of graft patency with dual therapy. However, the results
were in favour of combination therapy for patients with prosthetic
bypasses. The haemorrhagic risk doubled when warfarin was
added to aspirin. In another randomized study,311 warfarin (inter-
national normalized ratio 2.0–3.0) plus aspirin (325 mg/day) was
compared with aspirin (325 mg/day) alone in 56 patients with high-
risk vein grafts (defined as poor arterial run-off, suboptimal vein
conduit, and repeat interventions). At 3 years, patency and limb
salvage rates were significantly higher in those receiving warfarin
and aspirin, with in turn higher bleeding rates with this combi-
nation. Recently, the Clopidogrel and Acetylsalicylic Acid in
Bypass Surgery for Peripheral ARterial disease (CASPAR) random-
ized double-blind trial assessed the efficacy of aspirin plus clopido-
grel vs. aspirin alone to increase primary patency, limb salvage, and
survival in patients receiving a below-knee bypass graft.312 Among
the 851 patients enrolled, almost 70% had a venous graft and 30% a
prosthetic graft. After a mean follow-up of 1 year, no overall differ-
ence was found regarding the combined primary outcome
between the two groups. Subgroup analysis was in favour of a ben-
eficial effect of clopidogrel in association with aspirin in prosthetic
grafts. The number needed to treat using the dual antiplatelet
therapy to save one limb after below-knee surgery was dramati-
cally low, estimated at 10.2 patients.
The role of anticoagulation after infrainguinal balloon PTA and
stenting has been assessed in three prospective randomized
trials.313 None of these trials showed any significant improvement
in arterial patency with the use of anticoagulation therapy, while
bleeding complications increased.313 Yet, anticoagulation therapy
cannot be recommended routinely after lower extremity PTA or
stenting.
4.5.3.4 Stem cell and gene therapy for revascularization
The development of novel therapies to stimulate neovasculariza-
tion, known as therapeutic angiogenesis, is based on the use of
angiogenic factors or stem cells to promote revascularization and
remodelling of collaterals with the aim of ameliorating symptoms
and preventing amputation.
While several trials reported relief of ischaemic symptoms, func-
tional improvement, and prevention of amputation,314– 317 others
failed to confirm this early promise of efficacy.318– 320
For autologous cell transplantation in humans, bone marrow and
peripheral blood are rich sources of stem and progenitor cells.
Bone marrow is currently the most frequent source of cells used
for clinical repair trials, because it is easy to obtain and no
complex purification steps are required. Another advantage is
that it contains a variety of stem and progenitor cells with
suggested superiority over one selected type of progenitor cell.
With the many different cell types that can be used for stem cell
therapy, it is not yet clear which ones are the most promising.321
In a recent meta-analysis of 37 trials, autologous cell therapy was
effective in improving surrogate indexes of ischaemia, subjective
symptoms, and hard endpoints (ulcer healing and amputation).
Patients with thromboangiitis obliterans showed larger benefits
than patients with atherosclerotic LEAD. The TAMARIS study is
the largest randomized placebo-controlled trial of gene therapy in
CLI, including .520 patients from 30 countries with CLI and skin
lesions, unsuitable for standard revascularization. This study found
no statistical difference between the two groups regarding the
primary efficacy endpoint of death or first major amputation on
the treated leg, whichever came first (37.0% vs. 33.2%, P ¼
0.48).322 At present angiogenic gene and stem cell therapy are still
being investigated and it is too early to give firm recommendations.
4.5.4 Management of intermittent claudication
The management of intermittent claudication consists of optimal
risk factor control in order to improve the vital prognosis (see
Section 3.4) and the symptoms. Therapeutic options to relieve
symptoms are non-invasive (mostly exercise therapy and drug
therapy) or invasive (revascularization). An algorithm for the man-
agement of intermittent claudication is proposed in Figure 3. With
the increasing use of endovascular therapy to improve walking dis-
tance, there is an apparent need to compare it with ‘supervised
exercise training’. In a study of 51 patients with intermittent
Recommendations for antiplatelet and anticoagulant
therapy after revascularization
Recommendations Classa Levelb Ref c
Antiplatelet therapy with 
aspirin is recommended in all 
patients with angioplasty for 
LEAD to reduce the risk of 
systemic vascular events. 
I C
Dual antiplatelet therapy with 
aspirin and a thienopyridine 





Antiplatelet treatment with 
aspirin or a combination 
of aspirin and dipyridamole 
is recommended after 
infrainguinal bypass surgery. 
I A 308
 Antithrombotic treatment 
with vitamin K antagonists 
may be considered after 
autogenous vein infrainguinal 
bypass. 
IIb B 309
Dual antiplatelet therapy 
combining aspirin and 
clopidogrel may be considered 
in the case of below-knee 
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claudication, there was no significant difference in walking distance
or quality of life 2 years after treatment.323 More recently, a ran-
domized controlled study initiated in 151 patients with intermit-
tent claudication confirmed no difference in quality of life 12
months after intervention. However, this study showed a higher
cost for the endovascular intervention group.279 The adjuvant
benefit of endovascular therapy to ‘supervised exercise training’
associated with best medical therapy has been assessed in patients
with mild to moderate intermittent claudication.324 Although no
difference in quality of life was reported in this study, at 24
months the improvement in walking distance in the angioplasty
group was 38% greater than that in the control group in the
case of femoropopliteal lesions, and 78% in the case of aortoiliac
lesions. The ongoing Claudication: Exercise Versus Endoluminal
Revascularization (CLEVER) trial will provide important insights
into the indications of these therapeutic options in the manage-
ment of patients with intermittent claudication.325
4.5.4.1 Medical treatment
In patients with intermittent claudication, the primary goal is to
reduce the risk of CVD morbidity and mortality. This risk is
present in all patients with LEAD, including those with mild, atypi-
cal, and even no symptoms.2,326 Therefore, the management and
control of risk factors is necessary in every patient with LEAD,
to reach the goals of secondary prevention. Among them,
smoking cessation also provides the most noticeable improvement
in walking distance when combined with regular exercise training,
especially when lesions are located below the femoral arteries.
Symptoms can be improved by exercise training (preferably
supervised) and drug therapy. Walking tests on the treadmill
should be performed regularly to assess the evolution objectively.
Patients should also be advised to keep a logbook to follow their
home training and the evolution of their walking distance and
symptoms. The logbook can help the patient adhere to medical
advice. In the case of typical claudication, drug therapy to
improve walking distance can be initiated.
In many patients with mild to moderate symptoms, these first
steps will lead to a significant improvement in claudication and in
quality of life. In this case, training (and eventually drug therapy)
should be continued and the patients should be evaluated at
regular intervals. ABI should be controlled periodically, although
substantial functional improvement may not necessarily follow sig-
nificant ABI change. The risk factor profile should be checked reg-
ularly and treatment adapted accordingly.
4.5.4.2 Interventional therapy
In severe cases with disabling claudication, medical therapy includ-
ing ‘supervised exercise training’ is often insufficient to improve
no
yes
Management of intermittent claudication
Conservative therapy











Figure 3 Algorithm for the management of intermittent claudication. CV ¼ cardiovascular.
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symptoms, and imaging of the lesions should be performed to
define the exact location and characteristics of the lesions. This
will help to decide whether interventional treatment is indicated
and/or possible.
Evidence for any long-term benefit of revascularization over
supervised exercise and best medical therapy is inconclusive,
especially in patients with mild to moderate claudication.324
However, the expansion of endovascular therapy has prompted
many physicians to consider more liberal indications for percuta-
neous intervention. The indications for endovascular revasculariza-
tion also depend on the level of daily disability related to
claudication, when clinical and imaging features suggest a reason-
able likelihood of symptomatic improvement and there is insuffi-
cient response to exercise or pharmacological therapy. Owing to
the limited probability of improvement in symptoms with exercise
therapy in the case of aortoiliac lesions, revascularization should be
considered without initial conservative treatment. Surgery is
limited to extensive lesions without the possibility for endovascular
treatment. The management of patients with intermittent claudica-
tion is summarized in Figure 3.
4.5.5 Critical limb ischaemia (CLI)
4.5.5.1 Definition and clinical presentation
CLI is the most severe clinical manifestation of LEAD, defined as
the presence of ischaemic rest pain, and ischaemic lesions or
gangrene objectively attributable to arterial occlusive disease. It
implies a chronic condition, to be distinguished from acute limb
ischaemia (ALI) (see Section 4.5.6). An ankle pressure
,50 mmHg is usually recommended as a diagnostic criterion
because it includes most patients for whom rest pain or ischaemic
lesions do not improve spontaneously without intervention. Since
healing needs additional perfusion above that required for support-
ing intact skin, the ankle and toe pressure levels needed for healing
are higher than the pressures found in ischaemic rest pain. For
patients with ischaemic lesions or gangrene, CLI is suggested by
an ankle pressure of ,70 mmHg. Toe pressure ,30 mmHg
replaces the ankle pressure criteria in case of medial calcinosis.6
The investigation of the microcirculation (i.e. transcutaneous
oxygen pressure) is also helpful in some cases, not only for diag-
nostic and prognostic purpose, but also sometimes to determine
the level of amputation (Table 7).
Primary amputation rates range from 5% to 20%, mainly in
patients unsuitable for revascularization, who are neurologically
impaired or non-ambulatory.6,327 CLI is also a marker for general-
ized, severe atherosclerosis, with a three-fold risk excess of future
myocardial infarction, stroke, and vascular death compared with
patients with intermittent claudication.6
4.5.5.2 Therapeutic options
Comprehensive management requires multidisciplinary care to
control atherosclerotic risk factors, provide revascularization as
far as possible, optimize wound care, adapt shoe wear, treat infec-
tion, and initiate rehabilitation therapy (Figure 4).
The cornerstone of the management is arterial reconstruction
and limb salvage.328 Revascularization should be attempted
without delay in all patients presenting CLI, whenever technically
possible. The screening or assessment of coronary or cerebrovas-
cular diseases should not delay the management of patients with
CLI if clinically stable. Medical baseline therapy including at least
platelet inhibitors and statins should be initiated.329,330
All patients with CLI should be referred to a vascular specialist early
in the course of their disease, to plan revascularization. The most sig-
nificant change in the treatment of CLI is the increasing tendency to
shift from bypass surgery to less invasive endovascular procedures
as an accepted first-choice revascularization strategy including tibial
arteries, with bypass surgery reserved as a back-up option if necess-
ary.6 The main advantages of endovascular revascularization are the
low complication rates, ranging from 0.5% to 4.0%, high technical
success rates (even in long occlusions) approaching 90%, and an
acceptable short-term clinical outcome. The BASIL trial demon-
strated that rates of amputation-free survival are similar for surgery
and balloon angioplasty for at least 2 years after the procedure.302,331
The endovascular approach, including liberal use of stents above the
knee level, is justified as long as low rates of complications are encoun-
tered and the surgical landing zone for the distal anastomosis of a
potential secondary bypass remains unaffected by the interventional
procedure. In patients with extensive foot gangrene or sepsis, open
procedures possibly deliver more immediate pulsatile flow to the
limb; however, the higher morbidity of surgery and the risk of graft
Recommendations for patients with intermittent
claudication
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therapy is indicated when 
supervised exercise therapy is 
not feasible or available.
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claudication with symptoms 
affecting daily life activity, drug 




In the case of intermittent 
claudication with poor 
improvement after 
conservative therapy, 
revascularization should be 
considered.
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In patients with disabling 
intermittent claudication 
that impacts their activities 
of daily living, with culprit 
lesions located at the aorta/
iliac arteries, revascularization 
(endovascular or surgical) 
should be considered as first-
choice therapeutic option, 
along with the risk factor 
management.
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infection must be kept in mind.332 Very distal venous bypass grafts to
the pedal arteries are feasible and are characterized by an excellent
patency rate of 88% at 4 years.333,334
There are large discrepancies between the reported results of
arterial reconstruction,335 mostly because of the inappropriate
inclusion of patients with non-critical limbs in studies on CLI. Of
note, there is a lower risk group consisting of patients with rest
pain, and a higher risk group consisting of patients with true limb
ischaemia with major tissue loss. At 1 year, 73% of patients in the
low-risk group lost their leg or died if treated conservatively. For
those patients fitting the high-risk criteria, 95% of those treated con-
servatively required amputation within a year. In comparison, for
those high-risk patients who received reconstruction, only 25%
required major amputation.336 The primary efficacy endpoint of
therapy is vascular reconstruction patency and limb salvage,
whereas the patient-related main successful outcome includes main-
tenance of ambulation and independence. Despite acceptable patency
and limb salvage rates, reinterventions within 3 months and readmis-
sion to the hospital within 6 months occur in over a half of patients.
Independent predictors of failure include impaired ambulatory
status at presentation (HR 6.44), presence of infrainguinal disease
(HR 3.93), ESRD (HR 2.48), and presence of gangrene (OR 2.40).337
In patients with CLI unsuitable for revascularization, the only
drugs with some positive results within randomized studies are
prostanoids.338,339 However, due to some divergent results in
other studies, there is no conclusive evidence on effectiveness.340
The safety and efficacy of various forms of therapeutic angiogenesis
(gene or stem cell therapy) are promising, but robust evidence
from RCTs is needed. The benefits of spinal cord stimulation are
still debated, but a Cochrane review published in 2005 suggests
some efficacy.341
The management of patients with CLI is summarized in Figure 4.
4.5.6 Acute limb ischaemia (ALI)
ALI is related to a sudden decrease in arterial perfusion in the limb.
Thrombotic or embolic causes can be involved. Artery disease
progression, cardiac embolization, aortic dissection or emboliza-
tion, graft thrombosis, thrombosis of a popliteal aneurysm, entrap-
ment or cyst, trauma, phlegmasia cerulea, ergotism,
hypercoagulable states, and iatrogenic complications related to
cardiac catheterization, endovascular procedures, intra-aortic
balloon pump, extra-corporeal cardiac assistance, as well as
Table 7 Presentation of a patient with CLI
Assessment Feature Presentation to define CLI Remarks
History Duration of symptoms and clinical signs 
of CLI
>2 weeks Needs morphine analgesics to be controlled
Symptoms Rest pain Toe, forefoot Especially with elevation of limb (i.e. during night 
sleep). Calf pain/cramps do not constitute clinical 
presentation of CLI 
Ischaemic lesions Periungual, toes, heel, over-bone 
prominences
Infection Secondary complication: inflammation and 
infection
Probe-to-bone test Positive test identifies osteomyelitis with high 
specificity and sensitivity
Haemodynamics Absolute ankle pressure <50 mmHg 
or <70 mmHg
Plus rest pain
Plus ischaemic lesion(s) 
Absolute great toe pressure <30 mmHg To be measured in the presence of medial 
calcinosis (incompressible or falsely elevated ankle 
pressure,  ABI >1.40)
Transcutaneous partial oxygen pressure <30 mmHg Estimation of wound healing, considerable 
variability
ABI ¼ ankle–brachial index; CLI ¼ critical limb ischaemia.
Recommendations for the management of critical limb
ischaemia
Recommendations Classa Levelb Ref c
For limb salvage, 





When technically feasible, 
endovascular therapy may be 
considered as the first-line 
option.
IIb B 302, 331
If revascularization is 
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considered.
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Figure 4 Management of critical limb ischaemia. CVD ¼ cardiovascular disease.
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vessel closure devices are the potential causes of ALI. The viability
of the limb is mostly threatened in this context. Quick and proper
management is needed for limb salvage.
Once the clinical diagnosis is established, treatment with unfrac-
tionated heparin should be given.6,342 Analgesic treatment is often
necessary. The level of emergency and the choice of therapeutic
strategy depend on the clinical presentation, mainly the presence
of neurological deficiencies, and the thrombotic vs. embolic
cause. The clinical categories are presented in Table 8.
An irreversible or unsalvageable extremity may require amputa-
tion before deterioration of the patient’s clinical condition, although
attempts are usually made to save the limb, or at least to limit the
level of amputation. A viable limb mandates urgent imaging as well
as the assessment of major co-morbidities. In the case of severely
deteriorated renal function, detailed DUS imaging may replace
angiography. In some cases, a clear cardiac embolization in poten-
tially normal arteries can be treated by surgical embolectomy
without previous angiographic imaging. Otherwise, given the emer-
gency level of care, angiography can be performed with no previous
vascular ultrasound to avoid therapeutic delays.
Different revascularization modalities can be applied (Figure 5). The
options for quick revascularization consist of percutaneous catheter-
directed thrombolytic therapy, percutaneous mechanical thrombus
extraction or thromboaspiration (with or without thrombolytic
therapy), and surgical thrombectomy, bypass, and/or arterial repair.
The therapeutic strategy will depend on the type of occlusion (throm-
bus or embolus) and its location, duration of ischaemia,
co-morbidities, type of conduit (artery or graft), and therapy-related
risks and outcomes. Owing to reduced morbidity and mortality com-
pared with open surgery, endovascular therapy is the initial treatment
of choice, especially in patients with severe co-morbidities, if the
degree of severity allows time for revascularization, and pending
local availability of an emergency interventional team. Treatment
results are best with an ALI duration ,14 days.6 Intra-arterial throm-
bolysis is the classic endovascular technique for thrombus removal.
Various techniques and different thrombolytic agents are currently
used.6 Intrathrombotic delivery of the thrombolytic agent is more
effective than non-selective catheter-directed infusion. Different
devices aiming at mechanical removal of the clot have been developed
and are commonly used alone or in combination with thrombolysis,
with the main advantage of decreasing delay to reperfusion. The
modern concept of the combination of intra-arterial thrombolysis
and catheter-based clot removal is associated with 6-month amputa-
tion rates ,10%.6 Systemic thrombolysis has no role in the treatment
of patients with ALI.
Based on the results of old randomized trials,343–345 there is no
clear superiority of thrombolysis vs. surgery on 30-day mortality or
limb salvage. Thrombolysis offers better results when applied within
the first 14 days after the onset of symptoms. Thrombectomy
devices have been proposed to treat ALI, but the benefits are not
well documented. After thrombus removal, the pre-existing arterial
lesion should be treated by endovascular methods or open surgery.
Based on clinical presentation and availability of an emergency
centre, surgical revascularization should be preferred when limb
ischaemia is highly threatening and catheter-based treatment
attempts may delay revascularization. Lower extremity four-
compartment fasciotomies are sometimes performed to prevent a
post-reperfusion compartment syndrome, especially in the setting
of class IIb and III ischaemia with surgical revascularization. In cases
of viable limb, open or endovascular revascularization may not be
possible, especially in the case of absent distal arteries, even after
primary in situ thrombolysis; the only option then is to stabilize the
ischaemic status with medical therapy (anticoagulation, prostanoids).


































Adapted from Rutherford et al., with permission.328
Recommendations for acute limb ischaemia
Recommendations Classa Levelb Ref c
Urgent revascularization 
is indicated for ALI with 
threatened viability (stage II). 
I A 6, 342
In the case of urgent 
endovascular therapy, 
catheter-based thrombolysis in 
combination with mechanical 
clot removal is indicated 
to decrease the time to 
reperfusion.
I B 6, 304
Surgery is indicated in ALI 
patients with motor or severe 
sensory deficit (stage IIB).
I B 304
In all patients with ALI, heparin 
treatment should be instituted 
as soon as possible.
I C -
Endovascular therapy should 
be considered for ALI patients 
with symptom onset 
<14 days without motor 
deficit (stage IIA).
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* Sometimes, differentiation between a salvageable and unsalvageable extremity 
is almost impossible. If the doubt is raised, any surgical or endovascular 
revascularization action is justified even in advanced profound ischaemia.
Figure 5 Decision-making algorithm in acute limb ischaemia.
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4.6 Multisite artery disease
4.6.1 Definition
Multisite artery disease is defined as the simultaneous presence of
clinically relevant atherosclerotic lesions in at least two major vas-
cular territories. Although patients with multisite artery disease are
encountered regularly in clinical practice, no randomized trials
have been designed to compare different treatment strategies,
and the available data originate only from subgroup analyses or
consecutive patient series.
The recent ESC/European Association for Cardio-Thoracic
Surgery guidelines on myocardial revascularization offer for the
first time specific recommendations for the management of
patients suffering from CAD associated with carotid artery
disease, renal artery disease, or LEAD.346
When dealing with a patient with multisite artery disease, one
must focus attention not only on lesion sites and inherent technical
difficulties related to specific treatment options, but also on the
overall clinical status of the patient, taking into account the pres-
ence of cardiovascular risk factors and co-morbidities. Conse-
quently, the treatment strategy should be chosen individually,
based more on clinical rather than technical issues. A multidisci-
plinary team approach is required.
The present guidelines address the impact of multisite artery
disease on prognosis, as well as the screening for and management
of multisite artery disease, taking into account the combinations
most relevant for clinical practice.
4.6.2 Impact of multisite artery disease on prognosis
In patients with atherosclerotic disease in one vascular site, the pres-
ence of co-existing disease in a different vascular bed is associated
with a higher risk of recurrent symptoms and complications in the
first site. In fact, among 828 patients enrolled in the Framingham
Study who had a myocardial infarction, those with a history of
stroke or symptomatic LEAD had a two-fold increase in the risk of
recurrent myocardial infarction.347 The REACH Registry enrolled
68 236 patients with either established atherosclerotic arterial
disease (CAD, LEAD, cerebrovascular disease; n ¼ 55 814) or
three or more risk factors for atherothrombosis (n ¼ 12 422).348
The incidence of cardiovascular death, myocardial infarction, stroke,
or hospitalization for atherothrombotic events at 1 year increased
with the number of symptomatic sites, ranging from 5.3% for patients
with risk factors only to 12.6, 21.1, and 26.3% for patients with one,
two, and three symptomatic sites, respectively (P ,0.001 for
trend).1 At 3 years, the rates of myocardial infarction/stroke/vascular
death/rehospitalization were 25.5% for patients with symptomatic
vascular disease in one vascular site vs. 40.5% for patients sympto-
matic in multiple vascular sites (P ,0.001).348 In a survey on 7783 out-
patients who had experienced an atherothrombotic event, the rate of
a first recurrent event at 1 year was almost doubled for patients with
multisite disease vs. single disease location.349
4.6.3 Screening for and management of multisite artery
disease
4.6.3.1 Peripheral artery disease in patients presenting with coronary
artery disease
Screening for and management of carotid artery disease, renal
artery disease, and LEAD in patients presenting with CAD are
addressed below.
4.6.3.1.1 Carotid artery disease in patients presenting with coronary
artery disease
4.6.3.1.1.1 Carotid artery stenosis in patients not scheduled for coronary
artery bypass grafting
In patients with CAD, the prevalence of severe carotid stenosis
increases concurrently with the severity of CAD and is a known
predictor of worse cardiovascular prognosis. Furthermore, a
complex morphology of carotid plaque, such as echolucent
plaque, is associated with heterogeneous coronary plaques and
clinically unstable CAD. In a general review of cohorts with con-
secutive CAD patients enrolled without exclusion criteria,350 an
average prevalence of .50, .60, .70, and .80% carotid steno-
sis was reported in 14.5, 8.7, 5.0, and 4.5% of patients, respectively.
Thus, although the association between carotid artery stenosis and
CAD is evident, the prevalence of significant carotid stenosis over
the entire cohort is relatively low. Therefore, systematic carotid
duplex screening is of limited value.
4.6.3.1.1.2 Carotid artery stenosis in patients scheduled for coronary
artery bypass grafting
The question of prophylactic carotid revascularization in patients
needing coronary artery bypass grafting (CABG) who also have a
severe carotid artery stenosis arises from the higher risk of
stroke in this population (Table 9).
4.6.3.1.1.2.1 Screening for carotid stenosis in patients undergoing coron-
ary artery bypass grafting
The prevalence of carotid stenosis in patients undergoing CABG
varies in the literature, because of patient specificities, selection
bias, DUS diagnostic criteria, and the extent of stenosis considered.
Several studies attempted to identify clinical risk factors for the
presence of significant carotid artery stenosis among patients
undergoing planned CABG.352 The most frequent risk factors are
increasing age, history of cerebrovascular disease, or the
co-existence of LEAD. Other risk factors mostly reported are
female sex, multivessel CAD, and smoking. These risk factors are
taken into consideration in the ESC/EACTS guidelines on myocar-
dial revascularization.346 The criteria for screening carotid artery
disease in patients undergoing CABG differ slightly from their
expert-based recommendation, based on data from a study
which assessed the efficacy of a clinical score to propose carotid
DUS scanning in patients undergoing CABG.352 The authors
Table 9 Risk of stroke related to CABG
Patient category Stroke risk (%)
No carotid stenosis 1.4–3.8
Unilateral >50% carotid stenosis 3.0
Bilateral >50% carotid stenosis 5.0
Carotid occlusion 7.0
Previous stroke or TIA 8.5
CABG ¼ coronary artery bypass grafting; TIA ¼ transient ischaemic attack.
Modified from Blacker et al.351
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identified four independent risk factors for carotid stenosis in can-
didates for CABG: age .70 years, neck bruit, history of cerebro-
vascular disease, and presence of clinical or subclinical LEAD. In a
prospective assessment, they found that performing DUS scanning
only in patients with at least one of these risk factors detected
100% of those with a carotid stenosis .70%, and decreased the
number of useless scans by 40%. This approach does, however,
need validation in a multicentre study.
4.6.3.1.1.2.2 Management of carotid artery disease in patients under-
going coronary artery bypass grafting
It is unclear whether the benefits expected from CEA in the case
of asymptomatic carotid artery stenosis are similar in those with
concomitant CAD, and no specific randomized trial has been con-
ducted in CAD patients with asymptomatic carotid stenosis. The
Asymptomatic Carotid Atherosclerosis Study (ACAS) trial53
found no interaction between perioperative outcomes after CEA
and a history of myocardial infarction. A subgroup analysis of the
ACST54 observed long-term benefits with carotid surgery similar
to those for the overall sample in the subset of 830 patients
with CAD. However, the occurrence of stroke after CABG is mul-
tifactorial. In patients with carotid stenosis who undergo CABG
without intervention on the carotid arteries, only 40% of post-
operative strokes are ipsilateral to the carotid lesion. Besides,
only a quarter of the strokes in patients with combined carotid
and coronary surgery are exclusively ipsilateral to the stenotic
carotid artery.353 In fact, the most common single cause of
stroke after CABG is embolization with atherothrombotic debris
from the aortic arch, while atrial fibrillation, low cardiac output,
and hypercoagulation states resulting from tissue injury also con-
tribute to the risk of stroke. Thus, the presence of carotid stenosis
appears more as a marker of high risk of stroke after CABG rather
than the causal factor. Only those patients who have symptomatic
carotid artery disease and those with asymptomatic bilateral
carotid artery stenosis or unilateral carotid occlusion are definitely
at higher risk of stroke during cardiac surgery, compared with
patients without carotid artery stenosis.351,354
Owing to the multitude of causes of stroke during CABG, pro-
phylactic carotid revascularization before coronary surgery offers a
partial solution for stroke risk reduction, at the expense of the risk
related to the carotid revascularization itself, including the risk of
myocardial infarction if carotid surgery is considered before coron-
ary surgery in patients who often have severe CAD. Irrespective of
whether the patient will undergo prophylactic carotid revasculari-
zation, the risk of stroke in these patients is overall higher than in
the absence of CAD. The 30-day rate of stroke/death after com-
bined (either synchronous or staged) CABG + CEA353,355 –363 or
CABG + CAS363 – 368 is .9% in most reports (ranging from 4.0%
to 19.2%). On the other hand, a recent study reported a 5-year
rate of death/stroke or myocardial infarction as low as 8% after iso-
lated CABG in low-risk patients with asymptomatic carotid steno-
sis .70%.369 Thus, in the absence of clear proof that CEA or CAS
is beneficial in patients undergoing CABG, all patients should be
assessed on an individual basis, by a multidisciplinary team including
a neurologist. Based on trials in patients with symptomatic carotid
disease, it is reasonable to propose carotid revascularization (see
Section 4.1.1.3.2) in patients scheduled for non-emergency
CABG with recent (,6 months) TIA/stroke and symptomatic
carotid stenosis, although those trials do not address the specific
issue of patients undergoing coronary bypass.
Management of asymptomatic carotid stenosis should be delayed in
cases of acute coronary events, because of increased rates of unstable
carotid plaques concomitant to unstable CAD, with high periopera-
tive risk of stroke in the case of carotid intervention.350 Selected
patients with high-grade, asymptomatic carotid stenosis, particularly
in the case of bilateral stenosis, may benefit from prophylactic
carotid revascularization. The preoperative evaluation of such
patients should include a detailed neurological examination, history
aimed at unreported TIA symptoms, and a brain CT or MRI study
to assess the presence of ‘silent’ ipsilateral infarcts.
Choice of carotid revascularization method in patients scheduled for
coronary artery bypass grafting
Timaran et al. compared the in-hospital outcome of patients
who underwent CAS before CABG with those who were
treated by combined CEA and CABG between 2000 and
2004.363 During this 5-year period, 27 084 concurrent carotid
revascularizations and CABGs were done. Of these, 96.7% under-
went CEA–CABG, whereas only 3.3% (887 patients) had CAS–
CABG. Patients undergoing CAS–CABG had significantly lower
rates of post-operative stroke (2.4% vs. 3.9%; P ,0.001) and
tended to have lower rates of combined stroke and death (6.9%
vs. 8.6%; P ¼ 0.1) compared with patients undergoing CEA–
CABG, although in-hospital death rates were similar (5.2% vs.
5.4%, respectively). After risk stratification, CEA–CABG patients
had a 65% increased risk of post-operative stroke compared
with patients undergoing CAS–CABG (OR 1.65, 95% CI 1.1–
2.6; P ¼ 0.02). However, no differences in the risk of combined
Recommendations for screening for carotid artery
stenosis in patients undergoing CABG
Recommendations Classa Levelb Ref c
In patients undergoing 
CABG, DUS scanning is 
recommended in patients with 
a history of cerebrovascular 
disease, carotid bruit, 
age ≥70 years, multivessel 
CAD, or LEAD.
I B 352
Screening for carotid stenosis 
is not indicated in patients 
with unstable CAD requiring 






CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease;
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stroke and death were observed (OR 1.26, 95% CI 0.9–1.6; P ¼
not significant).
The most recent meta-analysis on the management of concomi-
tant coronary and carotid artery disease was published by Naylor
et al., in 2009.370 The results of different strategies (timing, revas-
cularization modalities) are presented in Table 10. Of note, these
results are stratified neither according to the coronary and neuro-
logical symptoms nor according to the severity of coronary and
carotid artery disease.
An overview of these results indicates no strong benefit of one
strategy over another, although some need further studies to
narrow their confidence intervals. Interestingly, the presence of
carotid artery stenosis may lead to reconsideration of the tech-
nique of surgical coronary revascularization. Indeed, the
co-existence of severe carotid disease in patients with CAD indi-
cates widespread atherosclerosis with high risk for the presence
of atherothrombotic lesions of the aortic arch, a risk factor for
stroke. The avoidance of cross-clamping of the aorta during
off-pump surgery may explain the lower rates of perioperative
stroke when combined with CEA, although the number of patients
subject to this strategy (n ¼ 324) is too low to draw firm
conclusions. Similarly, the higher risk of lesions of the aortic
arch, a risk factor for stroke during catheterization of the carotid
arteries, may explain why—although apparently less invasive—
CAS does not present superior results to CEA in this situation.
As expected, the staged approaches provide different myocardial
and neurological protection, depending on the timing of the two
interventions. This is probably the key issue when the staged
approach is considered, and the neurological or myocardial risk
may be prioritized according to the patient’s clinical presentation
as well as the level of severity of carotid and CADs.
Of note, in both the SAPPHIRE and CREST trials of CEA vs.
CAS, the 30-day rate of myocardial infarction after carotid revascu-
larization was significantly lower with CAS vs. CEA.79,98 Moreover,
in a recent meta-analysis evaluating 2973 patients enrolled in ran-
domized CAS vs. CEA trials, Wiesmann et al. reported a myocar-
dial infarction rate of 2.3% with CEA vs. 0.9% with CAS (P ¼ 0.03;
OR 0.37).373 However, although CAS appears to be associated
with a lower risk of periprocedural myocardial infarction com-
pared with CEA, the overall data including death and stroke
reported in Table 10 do not clearly favour one revascularization
strategy over another. If CAS is performed before elective
CABG, the need for double antiplatelet therapy usually delays
cardiac surgery for 5 weeks. Such deferral of CABG may
expose the patient to the risk of myocardial infarction between
CAS and CABG procedures (0–1.9%), and presents a major draw-
back of this treatment strategy.364,366,368 Recently, a few studies
described the results of synchronous CAS + CABG, with CAS
performed immediately before cardiac surgery.367,374 Such a strat-
egy yielded a more favourable 4.0% 30-day rate of death or
stroke.374 However, the bleeding risk during CABG, a factor pre-
dictive of long-term mortality, has not been considered extensively
when comparing CAS with CEA concomitant (or before) to
CABG.
More details on the management of carotid stenosis in patients
with CAD are given in Appendix 5.
Recommendations for the management of carotid
stenosis in patients undergoing CABG
Recommendations Classa Levelb
The indication for carotid revascularization 
should be individualized after discussion by a 
multidisciplinary team including a neurologist.
I C
If carotid revascularization is indicated, 
the timing of the carotid and coronary 
interventions should be decided according to 
the clinical presentation, level of emergency, 




CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease.
Table 10 Meta-analysis of cumulative results of
revascularization strategies, with an indication for
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CABG ¼ coronary artery bypass grafting; CAS ¼ carotid artery stenting; CEA ¼
carotid endarterectomy; MI ¼ myocardial infarction; TIA ¼ transient ischaemic
attack.
Two other recent meta-analyses on CAS + CABG371,372 provided similar results.
Adapted from Naylor et al.370
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4.6.3.1.2 Renal artery disease in patients presenting with coronary
artery disease
In patients with CAD, RAS .50% is found in 10–20% of cases,
mostly using renal angiography concomitant to cardiac catheteriza-
tion, with almost a quarter being bilateral.13,375 – 380 These studies
are concordant in reporting even higher rates in patients with
triple-vessel CAD, as well as in those with hypertension or renal
failure, although the use of contrast agents should be limited in
patients with renal failure. Other situations where renal artery
disease should be considered are recurrent episodes of heart
failure and/or refractory angina, pulmonary oedema, and renal
function deterioration after the introduction of ACE inhibitors or
angiotensin receptor antagonists.
In CAD patients with a suspicion of renal artery disease, as for
any other patient, DUS should be used as the first-line non-invasive
imaging test (see Section 4.4.3),171,172 even in the case of planned
cardiac catheterization, in order to limit the use of ionized contrast
agents and irradiation, and for cost issues. While CTA or MRA are
usual second-line imaging tests, in the case of planned coronary
angiography with a suspicion of renal artery disease after DUS
(or poor quality imaging) in the absence of renal failure, renal
angiography during the same procedure can be considered.
Although the co-existence of significant renal artery disease in
patients with CAD is not negligible, a systematic screening for
RAS does not appear reasonable because the management of
these patients is barely affected. The use of systematic renal angio-
plasty has been challenged recently by the results of the ASTRAL
trial191 (see Section 4.4.5.2), and there are no specific data for
patients who also suffer from CAD. Similarly, the presence of
renal artery disease does not affect the management of patients
with CAD, with the exception of renal failure after the use of
ACE inhibitors or angiotensin II receptor antagonists. Yet, the indi-
cations for screening renal artery disease in patients with CAD are
similar to those for any patient.
4.6.3.1.3 Lower extremity artery disease in patients presenting with cor-
onary artery disease
The co-existence of LEAD in CAD patients is associated with
worse prognosis. In the REACH registry,1 the 1-year rate of cardi-
ovascular death/myocardial infarction/stroke/hospitalization for
other atherothrombotic event(s) was 13.0% for patients with
CAD alone, and 23.1% for patients with both conditions. LEAD
is often under-recognized in CAD, as patients are largely asympto-
matic; in patients with limiting angina, failure to recognize the con-
dition may be because these patients exercise to a degree
insufficient to evoke intermittent claudication. Therefore, a sys-
tematic approach, with ABI measurement, could lead to better
identification of LEAD in patients with CAD.
In a cross-sectional study performed in primary care, ABI
detected LEAD in 26.6% of 1340 patients with CAD and no
other known location of atherothrombotic disease.381 The preva-
lence of LEAD was increased significantly in patients with diabetes
mellitus. Similar findings were reported in the Peripheral Arterial
Disease Awareness, Risk, and Treatment: New Resources for Sur-
vival (PARTNERS) study.382
In different studies, the prevalence of ABI ,0.90 can be esti-
mated at 25–40% in patients hospitalized for CAD,383– 385 while
only ,10% would be detected by clinical examination.386 –388
Among patients with CAD, older age, intermittent claudication
or atypical leg pain, smoking, diabetes, uncontrolled arterial hyper-
tension, and elevated LDL cholesterol can be identified as factors
suggestive of LEAD.
At any stage of CAD, the presence of LEAD is associated with a
more severe and poorer prognosis. In 234 consecutive patients
who underwent coronary angiography, Brevetti et al. found
higher rates of multivessel CAD in patients with LEAD (60% vs.
20%, P ,0.01), which were associated with higher concentrations
of C-reactive protein.389 In the Global Registry of Acute Coronary
Events (GRACE), the in-hospital mortality of patients with acute
Screening for RAS in patients planned for coronary
angiography
Recommendations Classa Levelb
DUS should be considered first in the case 
of clinical suspicion of renal artery disease in 
patients planned for coronary angiography.
IIa C
Renal angiography concomitant to cardiac 
catheterization may only be considered in the 




DUS ¼ duplex ultrasound; RAS, renal artery stenosis.
Recommendations for carotid artery revascularization
in patients undergoing CABG
Recommendations Classa Levelb
In patients undergoing CABG, with a <6-month history of 
TIA/stroke and corresponding carotid artery disease
Carotid revascularization is recommended in 
70–99% carotid stenosis.
I C
Carotid revascularization may be considered 
in 50–69% carotid stenosis, depending 
on patient-specific factors and clinical 
presentation.
IIb C
Carotid revascularization is not recommended 
if the carotid stenosis is <50%.
III C
In patients undergoing CABG with no history of TIA/
stroke within 6 months 
Carotid revascularization may be considered 
in men with bilateral 70–99% carotid stenosis 
or 70–99% carotid stenosis and a contralateral 
occlusion.
IIb C
Carotid revascularization may be considered 
in men with 70–99% carotid stenosis and 




CABG ¼ coronary artery bypass grafting; TIA ¼ transient ischaemic attack.
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coronary syndromes (ACS) as well as the presence of cardiogenic
shock was significantly higher in subjects with LEAD. At 6 months
the rate of major cardiovascular events was 14.6% in patients with
LEAD vs. 7.2% in those without.390 In the Monitoring of Trends
and Determinants in Cardiovascular Disease (MONICA) study,
the mortality rates in ACS were 18.8% and 13.1% in patients
with vs. without LEAD, respectively.391
The presence of LEAD is associated with a worse prognosis not
only in patients with ACS but also in those with chronic stable
angina as in the Coronary Artery Surgery Study (CASS), where
the mortality rate was 25% higher in patients with PAD as com-
pared with non-PAD patients, during a follow up of .10 years.386
After percutaneous coronary intervention (PCI), patients with
LEAD have a worse outcome. In a meta-analysis of eight studies,
the HRs for 30-day, 6-month, and 1-year mortality were, respect-
ively, 1.67, 1.76, and 1.46 (1.08–1.96) in patients with concomitant
LEAD.392 Similarly, the prognosis of CAD patients after CABG was
poorer in those with clinical or subclinical LEAD.393,394
In summary, patients with LEAD associated with CAD are at
twice the level of risk as those presenting with CAD alone.
However, whether the management of CAD patients should
differ in the case of concurrent LEAD is not obvious, because
there are no specific trials related to this situation. To date, the
co-existence of LEAD and CAD should only lead to closer atten-
tion, with a strict control of risk factors and the use of preventive
treatments. Lowering the target for LDL cholesterol from 2.6 to
1.8 mmol/L should be considered. Regarding the use of antiplatelet
therapy in stable CAD, given the greater benefits of clopidogrel vs.
aspirin found in those with LEAD, clopidogrel rather than aspirin
may be considered for the long-term treatment.38 In a post-hoc
analysis of the Clopidogrel for High Atherothrombotic Risk and
Ischaemic Stabilization, Management and Avoidance (CHARISMA)
study, there was a benefit of the combination of aspirin and clopi-
dogrel in patients with LEAD.40 Because of the post-hoc nature of
this analysis, the benefit of such an approach needs confirmation.
In the case of severe LEAD in CAD patients undergoing CABG,
the use of venous bypass should be limited as far as possible,
because this may lead to healing issues in the lower limbs, and
because the venous material should be spared for potential in
situ venous bypasses for the leg.
4.6.3.2 Screening for and management of coronary artery disease in
patients with peripheral artery disease
Management of CAD in patients presenting with carotid disease
and LEAD is addressed below.
4.6.3.2.1 Screening for and management of coronary artery disease in
patients presenting with carotid artery disease
Few studies have systematically used coronary angiography to define
the frequency of asymptomatic CAD in patients with carotid
disease. In a landmark study performed over two decades ago, hae-
modynamically relevant CAD was demonstrated in 40% of 200
patients while only 6% had absence of disease at angiography.398
In a recent prospective investigation in 390 patients undergoing elec-
tive CAS, systematic coronary angiography showed the presence of
one-, two-, and three-vessel disease and left main stenoses in 17, 15,
22, and 7% of patients, respectively. Only 39% of the patients with
significant coronary artery stenoses had cardiac symptoms.399
The only study involving the management of patients undergoing
CEA randomized 426 patients with no history of coronary disease
and with normal cardiac ultrasound and electrocardiography into
two groups, namely systematic coronary angiography and (if
needed) revascularization, or no coronary angiography.400 No
post-operative myocardial ischaemic events were observed
among patients undergoing coronary angiography, while nine
events were observed in the no-angiography group (P ¼ 0.01).
In conclusion, patients with carotid stenosis have a high preva-
lence of CAD—even in the absence of cardiac symptoms—and
are at risk of cardiovascular events. While CEA is considered as
an intermediate-risk procedure, the cardiac risk associated with
carotid revascularization may be lower with stenting than with
endarterectomy.79,98 With respect to screening with coronary
angiography and, if needed, coronary revascularization, before
vascular surgery, the results of the four available randomized
trials395 –397,400—none of them large-scale—have led to conflicting
results, and no firm recommendation can be made at this point for
patients undergoing carotid revascularization.
Recommendations for management of patients with
LEAD and concomitant CAD
Recommendations Classa Levelb Ref c
In patients with unstable CAD, 
vascular surgery should be 
postponed and CAD treated 
first, except when vascular 
surgery cannot be delayed due 
to a life- or limb-threatening 
condition.
I C -
The choice between 
CABG and PCI should be 
individualized, taking into 
consideration the clinical 
presentation of CAD and 
LEAD, and comorbidities.
I C -
In the case of LEAD in patients 
with stable CAD, clopidogrel 
should be considered as an 
alternative to aspirin for the 
long-term antiplatelet therapy.
IIa B 38
In patients with CAD, 
screening for LEAD by ABI 





risk vascular surgery may be 
considered in stable patients 
if they have persistent signs of 
extensive ischaemia or are at 







ABI ¼ ankle–brachial index; CABG ¼ coronary artery bypass grafting; CAD ¼
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4.6.3.2.2 Screening for and management of coronary artery disease in
patients presenting with lower extremity artery disease
4.6.3.2.2.1 Patients with lower extremity artery disease undergoing
surgery
This topic has been addressed extensively in the ESC guidelines for
pre-operative cardiac risk assessment and perioperative cardiac
management in non-cardiac surgery.47 Briefly, the goals of pre-
operative screening are to ensure that the perioperative period
is free of adverse cardiac events and to identify PAD patients
with a poor long-term prognosis in whom treatment and risk
factor modification may improve their outcome.
In LEAD patients, screening offers the opportunity to initiate
timely medication for secondary prevention of atherosclerotic
disease; this improves both direct post-operative outcome and
long-term survival. Factors that need to be considered in LEAD
patients for screening, include:
(i) Emergency surgery: chronic cardiovascular medication should
be continued during the procedure, and patients should be
referred for surgery without delay.
(ii)Unstable cardiac conditions: deferral of the procedure and
treatment of the underlying cardiovascular disease is
recommended.
(iii) Whether cardiovascular medications for secondary prevention
of atherosclerosis (b-blockers, statins, ACE inhibitors, aspirin)
are needed.
(iv) Whether work-up for the presence and extent of CAD is
warranted.
(v) How the results of the work-up will alter perioperative
management.
The first step is to identify unstable cardiac conditions (ACS,
arrhythmias, decompensated heart failure, severe valvular
disease) that require immediate treatment. Patients with LEAD
have a high risk for CAD: in a study of .1000 patients, only 8%
had a normal angiogram.401 Therefore, secondary prevention for
atherosclerotic complications is recommended before high-risk
surgery, including a low-dose, titrated b-blocker, statins, and
aspirin. In patients with reduced left ventricular function, ACE
inhibitors are recommended, according to the ESC guidelines.47
Overall, the second step is to assess the level of surgical risk.
However, peripheral vascular surgery is classified as high-risk
surgery. The third step is to assess functional capacity. If the
patient can achieve four or more metabolic equivalents without
symptoms, then it is acceptable to proceed with surgery. Patients
who have a functional capacity of less than four metabolic equiva-
lents are at higher risk. A metabolic equivalent of less than four is
equivalent to the inability to climb two flights of stairs or to run a
short distance. Obviously, for patients with lower extremity arter-
ial insufficiency, this might not always be possible to assess. In
patients with a low functional capacity, the cardiac risk of the pro-
cedure should be considered (Table 11).
Three randomized studies including patients with LEAD
addressed the role of prophylactic coronary revascularization in
stable patients scheduled for vascular surgery. The Coronary
Artery Revascularization Prophylaxis (CARP) trial was the first
to compare optimal medical therapy with revascularization (by
either CABG or PCI) in patients with stable ischaemic heart
disease prior to major vascular surgery.396 Of 5859 patients
screened, 510 were randomized. Patients were included on the
basis of a combination of cardiovascular risk factors and the detec-
tion of ischaemia on non-invasive testing. There was no difference
in the primary endpoint of mortality at 2.7 years after randomiz-
ation: 22% in the revascularization group vs. 23% in the
no-intervention group. In addition, no difference in the rate of peri-
operative myocardial infarction was detected (12% vs. 14%,
respectively). As a limitation, only a small proportion (8.9%) of
screened patients were randomized, and patients with left main
coronary disease were excluded by design from randomization.
DECREASE-V was a pilot study that applied a precise screening
methodology and a more contemporary perioperative medical
management.397 Patients at high risk for surgery underwent dobu-
tamine stress echocardiography or nuclear stress testing, and in the
presence of extensive ischaemia were randomized to either revas-
cularization or no revascularization. b-Blocker therapy was
initiated and aspirin was continued during surgery in all patients.
All patients (n ¼ 101) had had a previous myocardial infarction,
51% had ongoing angina, and 47% had congestive heart failure.
Three-vessel or left main disease was present in 75% of cases
and 43% had an ejection fraction of ≤35%. Both groups showed
a very high 30-day death or myocardial infarction rate at 30 days
(43% for revascularization vs. 33% for no revascularization; P ¼
not significant) and at 1 year (44% vs. 43%, respectively). The
fact that all patients who were randomly assigned to the revascu-
larization arm were compelled to undergo revascularization may
have increased the risk associated with revascularization in patients
with anatomy unsuitable for PCI and at high risk for CABG.397
A third study involved 208 consecutive patients scheduled for
elective surgical treatment of major vascular disease who were
at moderate to high cardiac risk for surgery. The patients were ran-
domized to mandatory pre-operative coronary angiography and
revascularization, if needed, or a selective strategy arm in which
angiography was performed only if indicated based on the results
Table 11 Cardiac risk stratification for non-cardiac
surgical procedures
High (reported cardiac risk often more than 5%) 
Aortic and other major vascular surgery
Peripheral vascular surgery
Intermediate (reported cardiac risk generally 1%–5%) 
Intraperitoneal and intrathoracic surgery
Carotid endarterectomy
Head and neck surgery
Orthopaedic surgery
Prostate surgery 






From Poldermans et al., with permission.47
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of non-invasive tests.395 The revascularization rates were 58% and
40% (P ¼ 0.01), respectively. The in-hospital major adverse cardi-
ovascular event rate did not differ between the two groups, but
at a mean follow-up of 58 months patients subject to the systema-
tic strategy of pre-operative coronary angiography had a statisti-
cally significant benefit in terms of freedom from major
cardiovascular events as well as of survival.
LEAD patients scheduled for intermediate-risk surgery can be
referred for surgery without additional testing for CAD. In patients
scheduled for high-risk surgery, the number of cardiac risk factors
should be assessed: angina pectoris, myocardial infarction, stroke
or TIA, renal dysfunction (creatinine .177 mmol/L; 2 mg/dL),
heart failure, and diabetes mellitus. In patients with three or
more risk factors, additional cardiac testing for the presence and
extent of CAD is recommended, if this will change management.
In selected cases one might also consider additional cardiac
testing as a means of patient counselling. If cardiac stress testing
shows no or only mild stress-inducible myocardial ischaemia,
additional invasive testing is not recommended. Again, all patients
should be prescribed statins, low-dose titration of b-blockers
before surgery, and aspirin; and those with systolic dysfunction
should have ACE inhibitors. Patients with extensive
stress-inducible myocardial ischaemia present a very difficult
group. Optimal medical treatment including b-blockers and
statins will not provide sufficient cardioprotection. However, pre-
operative prophylactic coronary revascularization is not generally
associated with an improved perioperative outcome in this
patient population. An individualized approach should be carried
out for these patients, taking into account the very high cardiac
risk of the planned surgical procedure and the possible harms of
not performing surgery (i.e. risk of rupture in patients with
abdominal aortic aneurysm). If it is decided to perform pre-
operative revascularization after multidisciplinary consultation, it
must be realized that the vascular surgical procedure should be
postponed for ≥14 days for balloon angioplasty, for 3 months
for bare-metal coronary stent placement, and for 12 months for
drug-eluting coronary stent placement.47
In summary, perioperative cardiovascular complications are
common in LEAD patients and result in significant morbidity fol-
lowing non-cardiac surgery. All patients require pre-operative
screening to identify and minimize immediate and future risk,
with a careful focus on known CAD or risks for CAD and func-
tional capacity. The 2009 ESC guidelines47 are clear that non-
invasive and invasive testing should be limited to circumstances
in which results will clearly affect patient management or in
which testing would otherwise be indicated. b-Blockers, statins,
and aspirin therapy should be continued in patients already on
therapy and should be started in PAD patients undergoing
intermediate- or high-risk surgery.
4.6.3.2.2.2 Patients with non-surgical lower extremity artery disease
Beyond the specific situation where a patient with LEAD will
undergo vascular surgery, the goal of screening for CAD is to
identify LEAD patients with a poor long-term prognosis in
whom treatment and risk factor modification may improve their
outcome. The co-existence of significant vascular lesions in differ-
ent sites is a common feature of atherosclerosis, a systemic disease
that can affect virtually any of the arterial vessels.384,402 –404 The
importance of prompt diagnosis and treatment of CAD has been
repeatedly underscored. Half of patients with LEAD die from car-
diovascular complications, and as early as 1 year after diagnosis;
cardiovascular mortality rates are 3.7-fold higher than in patients
without LEAD.405 One-third of PAD patients have significant
CAD lesions. Of interest, asymptomatic CAD is usually indepen-
dently associated with traditional risk factors but also with the
severity and extent of non-surgical LEAD.
The pending question is whether such identification may
improve clinical outcomes in patients who are already in secondary
prevention programmes. Of importance, stable atherosclerotic
patients without previous ischaemic events experienced signifi-
cantly more events in the case of multisite artery disease,406 but
this does not preclude any prognostic improvement in the case
of prophylactic coronary revascularization. Screening asympto-
matic CAD in patients with LEAD would be interesting if it leads
to a different management from the one proposed for LEAD
patients without CAD. Asymptomatic CAD in patients with
LEAD is by definition stable, a situation in which coronary revascu-
larization is controversial, given the negative results of the Clinical
Outcomes Utilization Revascularization and Aggressive Drug
Evaluation (COURAGE) trial,407 which failed to demonstrate the
superiority of coronary revascularization over optimal medical
therapy. However, this trial excluded situations in which revascu-
larization was considered as necessary, especially patients with a
poor ejection fraction and those with left main coronary artery ste-
nosis .50%. These situations are not infrequent in patients with
severe and extended LEAD, which is frequently associated with
multisite artery disease. In the absence of any specific trial in
LEAD patients, the screening and management of CAD may be
considered after a multidisciplinary discussion for each case.
5. Gaps in evidence
Solid evidence is still needed in many aspects of the management
of PAD. In numerous situations, adequate trials are lacking and
sometimes the management of PAD is extrapolated from data
regarding CAD. In the field of interventional therapy, rapid
changes in available therapeutic techniques create the situation in
which clinical practice tends to follow technical developments
without evidence from randomized trials. In addition, the random-
ized studies often yield conflicting results because of technical
evolution and growth in the participants’ experience. Moreover,
PAD may involve multiple sites, creating a large number of clinical
scenarios that are difficult to investigate in a systematic way. All of
these aspects contribute to the broad spectrum of gaps in evi-
dence, of which the most relevant are listed below.
Carotid artery disease
(i) The benefits of statins in patients with symptomatic carotid
stenosis derive from the subgroup analysis of the SPARCL
trial; the treatment goals for LDL cholesterol levels cannot
be clearly defined. Even fewer data are available on the
benefits of statins in asymptomatic carotid stenosis.
(ii) The benefits of other preventive therapies, i.e. antiplatelet
drugs and ACE inhibitors, are not well assessed in carotid
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disease, especially in the case of carotid plaque with non-
significant stenosis, which is the most frequent situation.
(iii) The benefits of CEA in asymptomatic patients were proven in
RCTs performed before the modern era of cardiovascular
prevention, when medical therapy was almost non-existent
and patients .80 years of age were excluded; thus, both
CEA and CAS need to be evaluated against current optimal
medical therapy in asymptomatic carotid stenosis, with a par-
ticular focus on elderly patients.
(iv) The efficacy of EPDs during CAS has not been studied in ade-
quately powered RCTs, and the available evidence is
conflicting.
(v) The optimal duration of dual antiplatelet therapy after CAS is
not well established.
Vertebral artery disease
(i) Almost no data are available on the clinical benefit of revascu-
larization of symptomatic VA stenosis, and on the comparison
between surgical and endovascular revascularization.
Upper extremity artery disease
(i) Almost no data are available on the clinical benefit of revascu-
larization of symptomatic subclavian artery stenosis/occlusion,
and on the comparison between surgical and endovascular
revascularization.
(ii) Little is known about the natural course in UEAD.
Mesenteric artery disease
(i) No data are available on the comparison between surgical and
endovascular revascularization for symptomatic mesenteric
artery disease.
(ii) No data are available on the potential benefits of revasculari-
zation for asymptomatic mesenteric artery disease involving
two or more main visceral vessels.
Renal artery disease
(i) Large-size trials are still necessary to clarify the potential
benefits of RAS in patients with different clinical presentations
of renal artery disease.
(ii) Appropriate treatment of in-stent renal artery restenosis is not
yet defined, although several trials are under way.
Lower extremity artery disease
(i) The benefits of statins in LEAD patients derive mainly from
small studies or from subgroup analyses of large RCTs
focused on CAD patients; thus, the treatment goals for
LDL cholesterol levels in LEAD patients cannot be defined
clearly.
(ii) Data on the benefits of the combination of ‘supervised exer-
cise training’ and medical therapy are lacking.
(iii) Data on the potential benefit of endovascular revasculariza-
tion over supervised exercise for intermittent claudication
are limited.
(iv) The role of primary stenting vs. provisional stenting in aortoi-
liac disease needs to be evaluated.
(v) In the superficial femoral artery, the role of primary stenting
in TASC II type C lesions, the potential benefit of covered
stents for long superficial femoral artery occlusions, and
the optimal treatment of in-stent restenosis need to be
investigated.
(vi) The role of drug-eluting stents and drug-eluting balloons in
superficial femoral artery and below-the-knee interventions
has to be established.
(vii) Optimal treatment for popliteal artery stenosis needs to be
addressed.
(viii) The role of self-expanding stents for below-the-knee inter-
ventions is unclear.
(ix) Benefits and/or adverse effects of b-blockers in CLI must be
further evaluated.
(x) Optimal duration of dual antiplatelet therapy after LEAD
stenting, as well as potential benefit of long-term dual antiag-
gregation therapy in patients with advanced CLI should be
further investigated.
(xi) The role of gene or stem cell therapy in CLI needs further
studies.
Multisite disease
(i) The need for prophylactic carotid revascularization in patients
with asymptomatic carotid stenosis scheduled for CABG is
still unclear.
(ii) The preferred timing of CABG associated with carotid revas-
cularization (synchronous or staged) is still unclear.
(iii) If future studies confirm the benefits of carotid revasculariza-
tion in patients undergoing CABG, the optimal treatment
method (CAS vs. CEA) should be determined.
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